


# Increased ACTL6A occupancy within mSWI/SNF chromatin remodelers drives human squamous cell carcinoma

## Graphical abstract



## Authors

Chiung-Ying Chang, Zohar Shipony, Sherry G. Lin, ..., Kyle M. Loh, William J. Greenleaf, Gerald R. Crabtree

## Correspondence

crabtree@stanford.edu

## In brief

Chang et al. find that ACTL6A plays a dosage-sensitive role underlying squamous cell carcinoma (SCC). Early in the course of the development of SCC, ACTL6A gene amplification increases its normally unsaturated occupancy within BAF complexes, leading to epigenetic derepression by polycomb redistribution and increased chromatin loading of TEAD-YAP.

## Highlights

- ACTL6A occupancy in the BAF complex is substoichiometric in normal epithelial cells
- SCC cells upregulate ACTL6A, thus increasing ACTL6A assembly with the BAF complex
- ACTL6A mediates co-dependent chromatin loading of BAF and TEAD-YAP complexes
- ACTL6A upregulation counteracts polycomb-mediated repression at SCC signature genes

Article

# Increased ACTL6A occupancy within mSWI/SNF chromatin remodelers drives human squamous cell carcinoma

Chiung-Ying Chang,<sup>1,2,7</sup> Zohar Shipony,<sup>3,7</sup> Sherry G. Lin,<sup>1,2</sup> Ann Kuo,<sup>1,2</sup> Xiaochen Xiong,<sup>4,5</sup> Kyle M. Loh,<sup>4,5</sup> William J. Greenleaf,<sup>3,6</sup> and Gerald R. Crabtree<sup>1,2,5,8,\*</sup>

<sup>1</sup>Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA

<sup>2</sup>Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA

<sup>3</sup>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA

<sup>4</sup>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA

<sup>5</sup>Department of Developmental Biology, Stanford University School of Medicine, Stanford, CA 94305, USA

<sup>6</sup>Department of Applied Physics, Stanford University, Stanford, CA 94305, USA

<sup>7</sup>These authors contributed equally

<sup>8</sup>Lead contact

\*Correspondence: [crabtree@stanford.edu](mailto:crabtree@stanford.edu)

<https://doi.org/10.1016/j.molcel.2021.10.005>

## SUMMARY

Mammalian SWI/SNF (BAF) chromatin remodelers play dosage-sensitive roles in many human malignancies and neurologic disorders. The gene encoding the BAF subunit actin-like 6a (ACTL6A) is amplified early in the development of many squamous cell carcinomas (SCCs), but its oncogenic role remains unclear. Here we demonstrate that ACTL6A overexpression leads to its stoichiometric assembly into BAF complexes and drives their interaction and engagement with specific regulatory regions in the genome. In normal epithelial cells, ACTL6A was substoichiometric to other BAF subunits. However, increased ACTL6A levels by ectopic expression or in SCC cells led to near saturation of ACTL6A within BAF complexes. Increased ACTL6A occupancy enhanced polycomb opposition genome-wide to activate SCC genes and facilitated the co-dependent loading of BAF and TEAD-YAP complexes on chromatin. Both mechanisms appeared to be critical and function as a molecular AND gate for SCC initiation and maintenance, thereby explaining the specificity of the role of ACTL6A amplification in SCCs.

## INTRODUCTION

Mammalian SWI/SNF (also known as BAF) complexes belong to a family of ATP-dependent chromatin remodelers, which contain an ATPase motor that binds nucleosomes and distorts or disrupts DNA-histone contacts (Clapier et al., 2017; He et al., 2020; Mashtalir et al., 2020). The enzymatic remodeling activity of the BAF complex allows DNA binding proteins like transcription factors to access their recognition sites for gene regulation, as well as other proteins involved in various nuclear processes, including DNA repair and decatenation (Barisic et al., 2019; Clapier et al., 2017; Kadoch and Crabtree, 2015). Interestingly, BAF complex composition is dynamic in that various assemblies from its 15 subunits encoded by 29 genes can be formed in a given cell and play distinct roles across the genome and in different cell types (He et al., 2020; Mashtalir et al., 2020; Wang et al., 1996; Wu et al., 2009). Although they lack sequence-specific DNA recognition, BAF subunits contain domains involved in binding to diverse histone modifications, AT-

rich sequences, cruciform DNA structures, and chromatin and transcriptional regulators that act in concert to guide BAF complex targeting over the genome (Kadoch and Crabtree, 2015). Unique alterations in BAF complex composition during development and in response to signaling further specialize it for engaging specific transcriptional programs (Wu et al., 2009). Still, the biochemical and structural properties conferred by individual subunits to diversify the remodeler's genomic targeting and recruitment of distinct transcriptional regulators remain largely undefined.

The distinct roles of individual subunits in BAF complexes have gained attention, because alterations in different subunits cause specific cancers and are found collectively in more than 20% of all human cancers (Kadoch et al., 2013; Shain and Pollack, 2013). Frequently, these mutations, such as those found on *ARID1A*, are heterozygous and loss of function, indicating that BAF subunits are dosage sensitive and that the complex functions as a tumor suppressor. Dosage-sensitive roles for several subunits are also seen in the development of the nervous

system and contribute to autism and intellectual disability (Ronan et al., 2013; Wenderski et al., 2020). Although the BAF complex is generally considered a tumor suppressor, some cancers bear gain-of-function BAF alterations, as in synovial sarcomas, in which a chromosomal translocation at *SS18* results in an oncogenic *SS18-SSX* fusion, which retargets BAF across the genome to reverse polycomb-mediated repression and activate oncogenes including *SOX2* (Clark et al., 1994; Kadoch and Crabtree, 2013; McBride et al., 2018). Thus, alterations in individual subunits compromise specific biologic actions of BAF complexes, and identifying the underlying mechanisms holds potential for the development of targeted therapy (Kadoch and Crabtree, 2015; Mashtalir et al., 2020; Wilson and Roberts, 2011).

The BAF-subunit gene encoding actin-like 6a (*ACTL6A*, originally called *BAF53A*) (Zhao et al., 1998) is located on human chromosomal segment 3q26, an amplification hotspot in multiple SCC types, including SCCs in the lung, skin, cervix, and oral mucosa (Ciriello et al., 2013; Heselmeyer et al., 1996; Speicher et al., 1995; Tonon et al., 2005). The amplification event occurs early in the course of lung SCC (LUSC) development and persists to the metastatic stage; thus, it is deemed critical to both tumor initiation and progression (Jamal-Hanjani et al., 2017). Several driver genes in this amplicon, including *PIK3CA*, *SOX2*, and *TP63*, have been identified (Bass et al., 2009; Keyes et al., 2011; Simpson et al., 2015; Watanabe et al., 2014), but the role *ACTL6A* plays in SCC oncogenesis is less clear.

SCC tumors arise from epithelial tissues, and in epidermis, *ACTL6A* expression appears in basal keratinocytes (KC) and wanes as cells undergo terminal differentiation (Bao et al., 2013). *ACTL6A* overexpression leads to an expanded basal layer of the epithelium, and conversely, loss of *ACTL6A* induces keratinocyte differentiation (Bao et al., 2013). *ACTL6A* also promotes the proliferation of other adult stem cells, including hemopoietic and neural stem cells (Krasteva et al., 2012; Lessard et al., 2007). In head-and-neck SCC (HNSC) cells, *ACTL6A* was found to interact with co-amplified *TP63* to co-regulate genes promoting proliferation and suppressing differentiation (Saladi et al., 2017). *ACTL6A* and  $\beta$ -actin form the actin-related protein (ARP) module in BAF complexes and bind the helicase/SANT-associated (HSA) domain of SMARCA4 (BRG1) or SMARCA2 (BRM) ATPases (He et al., 2020; Mashtalir et al., 2020; Szerlong et al., 2008). Unlike actin, *ACTL6A* does not have ATPase activity (Zhao et al., 1998). In yeast, homologs of *ACTL6A*, *Arp7/9*, increase the efficiency of ATP utilization by the yeast SWI/SNF complex (Szerlong et al., 2008). Nevertheless, the oncogenic mechanism driven by *ACTL6A* amplification and the roles of BAF complexes in promoting SCCs are still largely unclear, and understanding how *ACTL6A* amplification affects BAF complex composition and interaction surfaces may lead to new treatments for SCCs.

Here we find that amplification and overexpression of *ACTL6A*, which occurs in ~25% of all SCCs and about 40% of all lung SCCs, increases *ACTL6A*'s normally unsaturated occupancy within BAF complexes. This prompts polycomb redistribution, leading to the derepression of genes critical for SCC oncogenesis. In addition, increased *ACTL6A* incorporation directs the BAF complex's interaction with pro-oncogenic


TEAD-YAP transcriptional regulators. We find that BAF and TEAD-YAP complexes are co-dependent for chromatin binding, thereby creating a positive-feedback mechanism to maintain open chromatin for transcription. Using structure-guided mutagenesis, we found that mutations of two adjacent hydrophobic amino acids within *ACTL6A* enhanced the binding between BAF-TEAD/YAP complexes and promoted SCC growth, thereby defining a potential druggable target for SCCs with *ACTL6A* overexpression. Importantly, the dosage sensitivity of *ACTL6A*'s mechanism implies that a small reduction of *ACTL6A* function would be a viable therapeutic strategy against SCCs.

## RESULTS

### BAF complex alterations across multiple SCC types

To comprehensively assess the mutational burden to all BAF subunits in SCCs, we quantified the frequencies of SCC tumors with mutations, copy number variations, and mRNA expression alterations in all 29 BAF-subunit genes using available datasets from three SCC tissue types in the cBioPortal for Cancer Genomics (Cerami et al., 2012; Gao et al., 2013). Like chromosome 3q26, *ACTL6A* amplification was prominent, as previously reported (Ciriello et al., 2013; Heselmeyer et al., 1996; Saladi et al., 2017; Speicher et al., 1995; Tonon et al., 2005) (41% of LUSCs, 18% of HNSCs, and 14% of cervical SCCs; 24.3% on average) (Figure 1A). Nearly 50% of SCC tumors had increased *ACTL6A* expression (69% in LUSCs, 30% in HNSCs, and 51% in cervical SCCs) (Figure 1A). Another BAF-subunit gene, *BRD9*, was amplified (in 10% of combined SCC cases) (Figure 1A), but the amplification of *BRD9*, located on chromosome 5q15, infrequently overlapped with *ACTL6A* amplification, suggesting that either might be sufficient (Figure 1B). Surprisingly, the overall point mutation frequencies of BAF-subunit genes were low in all three SCCs despite their prevalence in other cancer types, including in basal cell carcinoma (BCC), in which 26% of cases harbor deleterious point mutations in *ARID1A* (Bonilla et al., 2016; Kadoch et al., 2013; Shain and Pollack, 2013) (Figure 1A).

Known oncogenes upregulated within the chromosome 3q25-28 amplicon include *SOX2*, *TP63*, and *PIK3CA* (Bass et al., 2009; Keyes et al., 2011; Simpson et al., 2015; Watanabe et al., 2014). Upregulation of *ACTL6A* was as prevalent as that of *PIK3CA* and more prevalent than that of *SOX2* and *TP63* across all three SCC types, suggesting *ACTL6A* upregulation is advantageous to SCC tumors and implying the potential significance of *ACTL6A* as a SCC biomarker or therapeutic target (Figure 1C). Although mutations in *PIK3CA* and BAF-subunit gene *ARID1A* co-occur to promote ovarian cancer (Chandler et al., 2015), *PIK3CA* mutations in SCCs were frequent but generally exclusive of *ACTL6A* amplification (Figure 1D). The median expression of *ACTL6A* in SCCs was 2- to 4-fold higher than in normal matched tissue samples (4.3-fold in LUSCs, 2.6-fold in HNSCs, and 2.8-fold in cervical SCCs) (Figure 1E). Thus, contrary to most other cancers, *ACTL6A* amplification, overexpression, or both, rather than point mutations in BAF complex subunits, are the dominant alterations of BAF complexes in SCCs, suggesting that a distinct composition might be important for SCC oncogenesis.



**Figure 1. *ACTL6A* amplification, overexpression, or both are the most frequent genetic alterations among 29 BAF-subunit genes in lung, head-and-neck, and cervical SCCs**


(A) Heatmaps for alteration frequencies of 29 BAF-subunit genes in three SCC types. mRNA-high/low: Z score threshold  $\pm 2$  relative to diploid samples. (B) Venn diagram between SCC tumors with amplification of *ACTL6A* and *BRD9*. Combined cases of lung, cervical, and head-and-neck SCCs. chr, chromosome. (C) Alteration frequencies of 133 genes co-amplified with *ACTL6A* in SCCs. (D) As in (B) for SCC tumors with *ACTL6A* amplification and *PIK3CA* missense mutations. (E) Boxplots of *ACTL6A* transcripts per million (TPMs) in tumors and their paired normal tissues. LUSC, lung SCC; CESC, cervical SCC and endocervical adenocarcinoma; HNSC, head-and-neck SCC; ESCA, esophageal carcinoma; T, tumor samples; N, normal tissue samples; RNA-seq: TCGA and GTEx gene expression data from GEPIA 2. \* $p < 0.01$ .

### Increased *ACTL6A* occupancy within BAF complexes in SCC cells

The dosage-sensitive roles of BAF subunits in neurodevelopment and cancers (Kadoch and Crabtree, 2015) led us to investigate how *ACTL6A* levels affect BAF complex composition in SCC cells. We determined the number of molecules per cell using quantitative western blotting in three SCC cell lines bearing overexpressed *ACTL6A*, along with primary normal human KC (cell type of origin for SCC) (Figures 2A and 2B; Figure S1A). Whole-cell lysates from equal numbers of cells of each cell line were used to quantify the amount of a specific protein from each line using a standard curve generated from purified recombinant proteins, followed by the calculation of protein mass and then the number of molecules per cell (Figure 2A). The total number of BAF complexes was estimated using an antibody that recognizes both SMARCA4 and SMARCA2, which are mutually exclusive catalytic subunits of BAF complexes. Surprisingly, we found that the number of *ACTL6A* molecules per normal ker-

atinocyte ( $111,686 \pm 9,850$ ) was only half the number of SMARCA4/SMARCA2 molecules ( $222,311 \pm 21,635$  per cell), suggesting that *ACTL6A* is substoichiometric within the complex in normal keratinocytes (Figure 2B). However, in all three SCC cell lines we examined, *ACTL6A* molecules were ~1.5- to 2.5-fold more numerous than SMARCA4/SMARCA2 molecules, which could result in more *ACTL6A*-containing complexes (*ACTL6A*:  $539,800 \pm 33,426$  molecules in FaDu [HNSC cell line],  $696,016 \pm 50,385$  molecules in NCI-H520 [lung SCC cell line],  $830,683 \pm 116,333$  molecules in T.T [esophageal SCC cell line]; SMARCA4/SMARCA2:  $323,542 \pm 25,374$  molecules in FaDu,  $389,563 \pm 9,539$  molecules in NCI-H520,  $315,344 \pm 20,536$  molecules in T.T) (Figure 2B).

To compare the occupancy of *ACTL6A* within BAF complexes in SCC cells to normal keratinocytes, we conducted SMARCA4 immunoprecipitation (IP) (Figure 2C). We found that the relative levels of SMARCA4-bound *ACTL6A* in FaDu SCC cells versus keratinocytes were ~7:1, which were substantially higher than



**Figure 2. Increased expression of ACTL6A in SCCs drives ACTL6A occupancy within BAF complexes**

(A) Outline of method for quantifying the number of molecules of a specific protein per cell from different cell lines.

(B) Quantifications of the number of ACTL6A molecules per cell compared with SMARCA4/SMARCA2. SCC cell lines: FaDu (head and neck), NCI-H520 (lung), and T.T (esophageal). KC, primary normal human keratinocytes. n = 3 experiments. Error bars indicate SEM. \*p < 0.05.

(C) Co-immunoprecipitation (coIP) experiments using SMARCA4 antibody. Shown are western blots and quantifications of relative levels of BAF subunits co-immunoprecipitated by SMARCA4 in SCC (FaDu) cells versus primary human KC. n = 3 experiments. Error bars indicate SEM. \*p < 0.05. n.s., not significant.

(D) CoIP experiments using SMARCA4 antibody in primary human KC transduced by lentivirus for ACTL6A overexpression and vector control. Shown are western blots and quantifications of relative levels of co-immunoprecipitated BAF subunits normalized to vector control. n = 3 experiments. Error bars indicate SEM. \*p < 0.05.

(E) Quantifications for coIP experiments by SMARCA4 antibody. Relative levels of co-immunoprecipitated ACTL6A in the ACTL6A-overexpressing condition normalized to vector control. FaDu, SCC cell line; HEK293T, human embryonic kidney 293T cells. Error bars indicate SEM. \*p < 0.05. n = 2–3 experiments.


the relative levels of SMARCA4 (~2:1), indicating a specific increase in ACTL6A occupancy within BAF complexes in SCC cells (Figure 2C). In contrast, for other BAF subunits, including SMARCC1, SMARCE1, and ARID1A, their occupancy within the complexes was unaltered in SCC cells, in which the relative co-immunoprecipitated levels of those subunits were similar to the relative levels of SMARCA4 (Figure 2C).

To specifically test whether ACTL6A expression levels can change ACTL6A stoichiometry, we reasoned that overexpressing ACTL6A in normal cells should increase ACTL6A incorporation into BAF complexes. Indeed, in keratinocytes transduced by lentivirus expressing ACTL6A, the levels of ACTL6A co-immunoprecipitated with SMARCA4 antibodies were 1.5- to 2-fold higher than in vector-control cells (Figure 2D). SMARCA4 levels remained unaltered, as did the incorporation of other BAF subunits, including SMARCC1 (Figure 2D). Overexpressing ACTL6A in another non-SCC line, HEK293T (human embryonic kidney 293T), also increased ACTL6A occupancy in BAF complexes (Figure 2E). However, elevating ACTL6A levels in FaDu SCC cells failed to increase its incorporation, indicating the occupancy of ACTL6A within BAF complexes is near saturation in SCC

cells (Figure 2E). The increased occupancy was not attributable to ACTL6A polymerization, because ectopically expressed ACTL6A-V5 did not bind untagged ACTL6A even though both were incorporated into BAF complexes (Figures S1B and S1C). Density sedimentation analysis of SCC cell nuclear extracts showed most ACTL6A co-migrated with SMARCA4, forming a full BAF complex (Figure S1D). Thus, these results reveal a dynamic occupancy of ACTL6A within BAF complexes in response to ACTL6A dosage. ACTL6A occupancy in BAF complexes is unsaturated in normal keratinocytes and becomes saturated upon its overexpression or in SCCs cells with ACTL6A amplification/overexpression.

### ACTL6A regulates the accessibility of specific regulatory regions over the SCC genome in a dosage-dependent manner

To identify accessible chromatin regions in the SCC genomes that depend on ACTL6A stoichiometry, we conducted ATAC-seq (assay for transposase-accessible chromatin using sequencing) in SCC cells upon ACTL6A knockdown by small interfering RNA (siRNA). ACTL6A knockdown (ACTL6A siRNA



**Figure 3. Genome-wide chromatin accessibility profiling identifies ACTL6A-dependent regulatory regions in SCC cells**

(A) MA plot for ATAC-seq analysis in FaDu SCC cells 72 h after transfection with ACTL6A siRNA (siACTL6A) and control siRNA (siControl). Color coded are significantly altered peaks with predicted TEAD binding motifs (navy) and without TEAD motif (light blue). False discovery rate (FDR) < 0.05. n = 2 experiments. n.s., not significant.

(B and C) Heatmaps and metagene plots for ATAC-seq analysis across ACTL6A-promoted (B) or ACTL6A-repressed (C) accessible regions with different levels of ACTL6A reduction by siRNA in FaDu SCC cells. CPM, counts per million.

(D and E) Enrichment for predicted transcription factor (TF) binding motifs in ACTL6A-promoted (D) or ACTL6A-repressed (E) accessible regions. Matches: number of peaks containing matched TF binding motifs.

(F) Genome browser tracks showing regions with differential reduction of accessibility upon different ACTL6A knockdown from ATAC-seq. The sites contained TEAD motifs and were also bound by SMARCC1, YAP, and TEAD1 identified by CUT&RUN.

(G) Immunofluorescence and quantifications of the percentage of cells with nuclear or cytoplasmic YAP showing unaltered YAP subcellular localization in FaDu SCC cells 72 h after siACTL6A knockdown versus siControl. Scale bars: 10  $\mu$ m.

(H) Quantifications for western blot (WB) signals of phospho-S127 YAP normalized to total YAP levels. Samples including whole-cell lysates (WCLs), cytoplasmic extracts (cyto), and nuclear extracts (nuclear) from FaDu cells 72 h after siRNA transfection. n = 3 experiments.

(I) qRT-PCR showing YAP/TEAD target genes regulated by ACTL6A. n = 3 experiments. Error bars indicate SEM. \*p < 0.05.

[siACTL6A]) resulted in ~90% reduction of ACTL6A levels and did not affect the levels of the other BAF subunits, SMARCA4 and SMARCC1, consistent with the notion that ACTL6A is not required for the stability and assembly of BAF complexes (Braun et al., 2021; Krasteva et al., 2012) (Figure S2A). ACTL6A knock-

down inhibited SCC cell proliferation (Figure S2B), as previously described (Saladi et al., 2017).

ACTL6A knockdown in SCC cells caused significant accessibility changes in 4,639 regulatory regions, in which 2,053 displayed decreased accessibility and 2,586 displayed increased

accessibility (Figure 3A). To see whether ACTL6A's effect on chromatin accessibility is dosage dependent and whether its varied dosage would change accessibility to different degrees or at different loci, we reduced ACTL6A siRNA doses to reach an intermediate or 60% ACTL6A reduction, in addition to our previous 90% knockdown condition (Figure S2C). Remarkably, the degree of accessibility changes correlated with ACTL6A levels (Figures 3B, 3C, and 3F). Across both ACTL6A-promoted and ACTL6A-repressed regions, intermediate reduction of ACTL6A resulted in a corresponding intermediate degree of chromatin accessibility decreases or increases, suggesting a dosage-sensitive role of ACTL6A in regulating chromatin accessibility in the SCC genome.

To identify regulatory elements specifically dependent on ACTL6A for accessibility in SCC cells, we conducted motif enrichment analysis across ACTL6A-promoted and ACTL6A-repressed accessible regions. The top-most significant sequence motifs enriched in ACTL6A-promoted sites were for TEA domain (TEAD1–TEAD4) transcription factors (Figures 3D and 3F). 818 of 2,053 ACTL6A-promoted sites contained predicted TEAD motifs, which by contrast were in only 219 of 2,586 ACTL6A-repressed regions (Figure 3A). CEBPA, POU-domain, and forkhead-box (FOX) binding motifs were also enriched in ACTL6A-promoted accessible regions, albeit to a lesser extent, whereas CTCF motifs were depleted in these sites, suggesting insulator elements may be refractory to ACTL6A loss (Figure 3D). 92% of ACTL6A-promoted accessible regions were outside gene promoters, implicating ACTL6A's role in promoting the accessibility of distal regulatory elements (Figure S2D). In contrast, 20% of ACTL6A-repressed regions were within gene promoters (Figure S2E), which were enriched for transcription factor motifs for AP-1 family members FOS and JUN (Figure 3E), likely reflecting the reaction to genotoxic stress characteristic of BAF-subunit depletion (Dykhuisen et al., 2013; Smeyne et al., 1993; Wenderski et al., 2020).


The decreased TEAD accessibility by ACTL6A reduction in SCC cells suggests ACTL6A might regulate the oncogenic activity of TEAD-mediated pathways. TEADs, which form complexes with transcriptional co-activators YAP/TAZ, act downstream of the mechano-transduction and Hippo pathway that are involved in tumorigenesis, organ size control, regeneration, and cancer resistance to targeted, immuno-, and chemotherapies (Nguyen and Yi, 2019; Yu et al., 2015a; Zanconato et al., 2016). In mammalian skin, YAP/TAZ promotes SCC initiation and progression (Debaugnies et al., 2018; Schlegelmilch et al., 2011; Vincent-Mistiaen et al., 2018). In *Drosophila*, Hippo signaling has been shown to depend on the Brahma (Brm)-associated proteins (BAP) complex, the fly SWI/SNF complex (Jin et al., 2013; Oh et al., 2013). However, the underlying mechanism remains elusive. Previous studies suggest ACTL6A loss inhibits YAP activity by upregulating the WWC1 gene, which encodes a scaffold protein in the Hippo pathway and promotes YAP retention in the cytoplasm (Saladi et al., 2017). However, we did not observe increased levels of cytoplasmic YAP by immunostaining in siACTL6A SCC cells relative to control siRNA (siControl) cells (Figure 3G). Western blotting also did not show changes in total YAP protein levels (Figure S5G, input lanes) or YAP S127 phosphorylation levels, which promotes its cytoplasmic retention (Yu

et al., 2015a) (Figure 3H). WWC1 expression also remained unaltered upon ACTL6A knockdown (Figure S2F). Thus, the accessibility changes at TEAD enhancers upon ACTL6A loss are not caused by YAP translocating to the cytoplasm in these SCC cells. Instead, it implies that ACTL6A-BAF complexes directly promote the remodeling of local chromatin at TEAD enhancers.

The decreases in accessibility at predicted TEAD motifs were accompanied by reduced expression of TEAD/YAP/TAZ target genes in ACTL6A-knockdown SCC cells (Figure 3I; Figure S3A). Using RNA sequencing (RNA-seq) analysis, we identified 188 differentially expressed genes between siACTL6A and siControl conditions in at least two of the three SCC cell lines, which included previously identified TEAD/YAP/TAZ target genes (Zhang et al., 2009) (Figures S3A and S3B). These targets were validated by quantitative reverse transcription PCR (qRT-PCR) of independently prepared samples (Figure 3I). The expression of *TEAD1–TEAD4*, *YAP*, and *TAZ* was unaltered in ACTL6A-knockdown SCC cells (Figure S3C). Thus, ACTL6A does not regulate the transcription of *TEAD/YAP/TAZ*, and the reduced expression of their target genes was not due to reduced expression of *TEAD/YAP/TAZ*. Although *TP63* and *SOX2* are co-amplified with ACTL6A in SCCs (Figure 1C), the expression of their target genes (Watanabe et al., 2014) was largely unchanged upon ACTL6A knockdown (Figure S3D), suggesting ACTL6A is not essential for the downstream transcriptional programs of *TP63* and *SOX2*. It is possible that the pioneer factor property of *SOX2*, which can initiate chromatin opening (Dodonova et al., 2020) or the remodeling activity from residual BAF complexes, is sufficient to enable *SOX2*'s chromatin binding.

### **BAF complexes and TEAD-YAP co-localize on chromatin and modulate the accessibility of TEAD enhancers through a co-dependent mechanism in SCC cells**

If the accessibility of TEAD enhancers is directly modulated by ACTL6A-BAF complexes, ACTL6A-BAF complexes should co-bind with TEAD-YAP across the genome. To test this prediction, we conducted CUT&RUN to profile the distribution of TEAD1, YAP, and BAF complexes (SMARCC1, a DNA binding subunit of BAF complexes) genome-wide. As expected, the regions bound by TEAD1 and YAP largely overlapped (Figures 4A and 4B). Remarkably, 91% of TEAD1-YAP co-bound regions were also bound by SMARCC1, indicating their co-localization on chromatin (Figures 3F, 4A, and 4B). Furthermore, 79% of YAP/TEAD1/SMARCC1 co-bound regions were at active enhancers marked by the histone modifications histone H3 lysine 27 acetylation (H3K27ac) and histone H3 lysine 4 monomethylation (H3K4me1), concordant with earlier observations of TEAD-YAP binding at active enhancers (Stein et al., 2015; Zanconato et al., 2015) (Figure 4B; Figure S4A). A *de novo* motif search identified TEAD motifs in the 6,251 shared peaks, confirming the specificity of YAP and TEAD1 CUT&RUN profiling (Figure S4B). Although BAF complex-bound regions were enriched most for binding motifs of FOSL2 (JUNB) and SP2 (Figure S4C), the accessibility decreases upon ACTL6A loss were largely at TEAD motifs (Figures 3A and 3D), indicating a specific effect of ACTL6A in the complex on promoting TEAD chromatin binding. The CUT&RUN profiling confirmed the presence of YAP and TEAD1 at ACTL6A-promoted accessible regions marked by



**Figure 4. Co-dependency between BAF complexes and TEAD-YAP for their chromatin loading**

- (A) Venn diagram showing the overlap of peaks of SMARCC1, YAP, and TEAD1 CUT&RUN in FaDu SCC cells.  $n = 2$  experiments.  
 (B) Heatmaps for CUT&RUN YAP peaks aligned with indicated CUT&RUN peaks.  
 (C) Metagene plots of SMARCC1, YAP, and H3K27ac CUT&RUN over ACTL6A-promoted accessible sites in siControl and siACTL6A cells.  
 (D) Heatmaps and metagene plots for ATAC-seq and CUT&RUN of SMARCC1, YAP, and TEAD1 across regions with reduced YAP binding 48 h after YAP/TAZ siRNA (siYAP/TAZ) knockdown versus siControl.  
 (E) Genome browser tracks of ATAC-seq and CUT&RUN of SMARCC1, YAP, and TEAD1 in siACTL6A, siYAP/TAZ, and siControl cells.


enhancer mark H3K4me1, in contrast to low YAP and TEAD1 levels at ACTL6A-repressed regions, which spanned histone H3 lysine 4 trimethylation (H3K4me3)-marked promoters (Figure S4D). ACTL6A knockdown reduced the binding of YAP-TEAD1 at enhancers that also lost accessibility, accompanied by reduced levels of the active mark H3K27ac and SMARCC1 (Figures 4C and 4E). SMARCC1 peaks at YAP, TAZ, and TEAD1-TEAD4 genes were unaltered by ACTL6A loss, supporting the notion that ACTL6A does not affect YAP/TAZ/TEAD transcription (Figure S4E). Altogether, these results indicate that BAF complexes and TEAD-YAP co-bind across the genome and that ACTL6A functioning within the BAF complex plays a direct and specific role in targeting BAF complexes to TEAD-YAP enhancers and preparing the chromatin landscape to allow TEAD-YAP chromatin binding and transcription activation at their target loci.

The reduced SMARCC1 binding accompanied by reduced YAP binding on chromatin upon ACTL6A loss prompted us to see whether TEAD-YAP/TAZ complexes also facilitate the BAF complex's chromatin recruitment. Knocking down YAP/TAZ (YAP/TAZ siRNA [siYAP/TAZ]) reduced the expression of their target genes, including *CTGF* and *OLR1*, as expected and did not alter ACTL6A levels (Figure S4F). By CUT&RUN, we found substantial regions in siYAP/TAZ cells versus siControl cells

with reduced YAP and TEAD1 chromatin binding (Figure 4D). SMARCC1 chromatin binding across these regions was also significantly diminished and corresponded with reduced accessibility as analyzed by ATAC-seq, suggesting TEAD-YAP/TAZ can recruit BAF complexes to chromatin (Figure 4D). Thus, BAF and TEAD-YAP/TAZ complexes are mutually dependent on each other for stable chromatin binding (Figure 4E). The presence of TEAD-YAP/TAZ at enhancers recruits BAF complexes; meanwhile, ACTL6A in BAF complexes facilitates the chromatin binding of TEAD-YAP/TAZ, creating a positive feedback mechanism to maintain the accessibility of TEAD enhancers and the expression of their target genes.

### Increasing ACTL6A levels induces TEAD-YAP binding to BAF complexes

The co-dependency of TEAD cognate motif accessibility on the presence of both ACTL6A-BAF and TEAD-YAP/TAZ complexes suggests an interaction between these two complexes and that ACTL6A incorporation might modulate this interaction. To test whether ACTL6A assembled into the BAF complex directly recruits TEAD-YAP, we conducted immunoprecipitation experiments. Using TEAD4 and pan-TEAD antibodies, we were able to co-immunoprecipitate SMARCC1 and several other BAF subunits from nuclear extracts of SCC cells (Figure 5A; Figure S5A).



**Figure 5. ACTL6A promotes the direct binding of TEAD-YAP to BAF complexes**

(A and B) CoIP experiments by TEAD4 (A) and YAP (B) antibodies using nuclear extracts from FaDu SCC cells.  
 (C) Workflow for *in vitro* binding experiments. BAF complexes and FLAG-YAP were purified separately under high-salt buffer conditions and then co-incubated under a low-salt buffer condition for *in vitro* binding examination.  
 (D) *In vitro* binding of purified FLAG-YAP and BAF complexes by SMARCA4 antibody immunoprecipitation (IP).  
 (E) CoIP experiments by YAP and immunoglobulin G (IgG) antibodies showing decreased binding of SMARCA4 with YAP in *ACTL6A* CRISPR-knockout (KO) FaDu SCC cells. Quantifications normalized to control. INO80, INO80 complex subunit.  
 (F) CoIP experiments by YAP and IgG antibodies in primary human keratinocytes overexpressing *ACTL6A* and vector control.  
 (G) Quantifications of (F) showing increased binding of YAP and BAF subunits upon *ACTL6A* overexpression. Normalized to vector control. n = 3 experiments. Mean ± SEM. \*p < 0.05.  
 (H) The human BAF complex cryo-electron microscopy (cryo-EM) structure (PDB: 6LTJ) showing the position of *ACTL6A* P373/P374 residues (marked in red) in the nucleosome-bound BAF complex. Cyan, *ACTL6A*; red, P373/P374 residues of *ACTL6A*; green, HSA domain of SMARCA4; yellow, nucleosomal DNA; olive, histone octamer.  
 (I) Quantifications of CoIP experiments by YAP antibodies in keratinocytes overexpressing WT, R377G, and P373S/P374G *ACTL6A*. Normalized to vector control. n = 3 experiments. Mean ± SEM. \*p < 0.05.  
 (J) Growth curves of FaDu SCC cells transduced with lentiviral constructs for *ACTL6A* CRISPR-KO and simultaneously reconstituted with KO-resistant WT, R377G, P373S/P374G *ACTL6A*, or vector control. n = 3 experiments. Error bars indicate SD.

Furthermore, the reciprocal immunoprecipitation with SMARCA4 and *ACTL6A* antibodies yielded TEAD proteins (Figures S5B and S5C). Antibodies to YAP also co-immunoprecipitated BAF subunits (Figure 5B). To confirm this interaction is direct, we developed an *in vitro* binding assay (Figure 5C). Increasing salt concentrations to 500 mM (high salt) can disrupt the BAF-YAP interaction (Figure S5D). Hence, we introduced FLAG-tagged YAP into cells and purified FLAG-YAP from the nuclear extract under the high-salt conditions, which co-precipitated TEAD but removed most BAF complexes (Figure S5E). We concurrently purified BAF complexes with a SMARCA4 antibody under high-salt conditions, which yielded minimal YAP (Figure S5F). After co-incubation under low-salt conditions, purified FLAG-YAP and purified BAF complexes were co-immunoprecipitated by the

SMARCA4 antibody (Figure 5D), suggesting the interaction is direct.

To examine whether the interaction of TEAD-YAP and BAF complexes depends on *ACTL6A*, we conducted *ACTL6A* loss-of-function and gain-of-function analyses. Reducing *ACTL6A* levels in SCC cells by siRNA or CRISPR-Cas9 diminished BAF complex binding to YAP (Figure 5E; Figure S5G). Remarkably, overexpressing *ACTL6A* in normal human keratinocytes, which increased *ACTL6A*-containing BAF complexes (Figure 2D), enhanced the interaction (Figures 5F and 5G; Figure S5H). We did not observe YAP binding to INO80, another *ACTL6A*-associated chromatin remodeler (Figure 5E). Thus, *ACTL6A* is necessary and sufficient for the interaction between BAF complexes and TEAD-YAP.

The WW domains of YAP recognize the PPxY motif on its interaction partners (Chen and Sudol, 1995). Although ACTL6A does not contain a PPxY motif, we speculated that a proline-rich loop structure (PPSMRLKLI; 373–381 aa) on ACTL6A that extends toward the nucleosomal DNA bound by the BAF complex (He et al., 2020) may serve as an alternative interaction point (Figure 5H). To examine the effect of ACTL6A P373S/P374G double mutations on the interaction between YAP and BAF complexes, we introduced P373S/P374G ACTL6A in human keratinocytes with wild-type (WT) ACTL6A as control and conducted YAP immunoprecipitation. Although WT ACTL6A overexpression is sufficient to enhance the interaction (Figures 5F and 5G), unexpectedly, we found that overexpression of P373S/P374G ACTL6A induced higher levels of YAP binding to BAF complexes than WT ACTL6A (Figure 5I). A nearby R377G mutation did not show this effect on BAF-YAP binding (Figure 5I). To examine whether the increased binding might promote SCC proliferation, we knocked out endogenous ACTL6A using CRISPR-Cas9 and simultaneously reconstituted it with mutated or WT ACTL6A. Reconstituting WT ACTL6A rescued the proliferation defects caused by ACTL6A knockout, and P373S/P374G mutants promoted SCC growth better than WT or R377G ACTL6A (Figure 5J). These mutations neither compromised ACTL6A stability nor altered its incorporation into BAF complexes (Figure S5I). Altogether, these results indicate that ACTL6A regulates TEAD-YAP activity to drive SCC growth by producing interaction surfaces on BAF complexes for TEAD-YAP binding.

### ACTL6A overexpression redistributes polycomb over the genome


The SWI/SNF complexes and polycomb-repressive complexes (PRCs) play opposing roles in epigenetic regulation. In flies, loss-of-function mutations in the SWI/SNF subunits suppress defects that are conferred by mutations in PRC1, indicating a rather dedicated relationship between these two classes of chromatin regulators (Tamkun et al., 1992). In synovial sarcoma, malignant rhabdoid tumors, and several other BAF-subunit-mutated cancers, PRCs are important primary targets of mammalian SWI/SNF or BAF complexes and distinct mutations in BAF complexes can result in either gain or loss of its ability to evict PRCs (Bitler et al., 2015; Ho et al., 2011; Kadoch and Crabtree, 2013; Kadoch et al., 2017; Kia et al., 2008; Stanton et al., 2017; Wilson et al., 2010). To determine early consequences of ACTL6A amplification and whether they are attributable to perturbation of the BAF-PRC balance, we examined by CUT&RUN the genome-wide distribution of the PRC2-modified histone mark histone H3 lysine 27 trimethylation (H3K27me3) in primary normal human keratinocytes following ACTL6A overexpression.

Remarkably, ACTL6A overexpression led to H3K27me3 redistribution over the genome (Figure 6A). We identified gene promoters with altered H3K27me3 deposition, most of which showed decreased H3K27me3 levels, consistent with previous studies that show BAF complexes rapidly and directly evict PRC by an ATP-dependent mechanism (Kadoch et al., 2017; Stanton et al., 2017) (Figure 6B). Affected promoters were primarily bivalent, i.e., marked by both H3K27me3 and H3K4me3, supporting BAF's role in maintaining bivalent chromatin states

(Stanton et al., 2017) (Figures 6B and 6C). Consistent with the effect of ACTL6A overexpression on H3K27me3 domains, knocking down ACTL6A caused increased H3K27me3 levels across the genome accompanied by a few sites with modestly reduced H3K27me3 levels (Figures S6A and S6B). To explore how changes in H3K27me3 levels upon ACTL6A overexpression affected transcription, we conducted RNA-seq analysis. As expected, alterations in H3K27me3 and transcription were largely negatively correlated. Genes with reduced H3K27me3 tended to have increased expression, and vice versa (Figure 6C). A subset of genes with altered H3K27me3 levels lacked significant changes in their expression, suggesting that H3K27me3 alterations induced by ACTL6A overexpression were likely direct consequences rather than secondary effects from transcriptional changes.

The decrease of H3K27me3 marks upon ACTL6A overexpression was not due to keratinocyte differentiation, which in contrast leads to a global loss of H3K27me3 and an accompanying decrease in ACTL6A (Bao et al., 2013; Ezhkova et al., 2009). Furthermore, the H3K27me3 levels at polycomb-repressed differentiation genes such as *KRT1* and *LOR* were unaltered (Figure S6C). The expression of keratinocyte differentiation genes (*KRT1*, *KRT10*, *IVL*, and *LOR*) and progenitor markers (*KRT14*, *KRT5*, and *TP63*) was also unchanged (Figure S6D). Consistent with the observation that conditional loss of BAF subunits decreases H3K27me3 levels in *HOX* clusters (Ho et al., 2011), we observed a gain of H3K27me3 in the *HOXB* locus upon ACTL6A overexpression (Figure 6C; Figure S6E). Thus, ACTL6A overexpression in normal human keratinocytes leads to a redistribution of H3K27me3 over the genome.

Because ACTL6A amplification is an early event in the pathogenesis of SCC (Jamal-Hanjani et al., 2017), we reasoned that overexpressing it in normal keratinocytes might initiate a program of SCC gene expression. If PRC redistribution is a major driving mechanism, then these SCC genes should be distinguished by PRC loss upon ACTL6A overexpression. To determine whether the polycomb target genes affected by ACTL6A dosage are also misregulated in SCC tumors *in vivo*, we examined their transcripts in SCC tumors versus normal tissues using TCGA/GTEX datasets available in GEPIA (Tang et al., 2017) (Figure 6D). We found 64 of the PRC targets displayed corresponding changes in their RNA levels in either LUSC or HNSC tumors compared with paired normal tissues, with  $p < 0.05$ . 47 genes that lost H3K27me3 upon ACTL6A overexpression were preferentially upregulated in LUSC or HNSC tumors, whereas 17 genes that gained H3K27me3 by ACTL6A overexpression were downregulated in LUSC or HNSC tumors (Figure 6D). The derepressed genes included *WNT7B* (Figures 6E and 6F). *WNT7B* encodes a Wnt ligand and has been found to contribute to skin carcinogenesis (Krimpenfort et al., 2019) and promote proliferation and invasion of oral SCC cells (Shiah et al., 2014). In pancreatic adenocarcinoma, *WNT7B* promotes tumors' anchorage-independent growth and sphere formation (Arensmann et al., 2014). ACTL6A overexpression in primary keratinocytes induced *WNT7B* upregulation and correspondingly reduced H3K27me3 levels at its bivalent promoter (Figure 6E). Two SMARCC1 CUT&RUN peaks near the H3K27me3 domain and within the *WNT7B* gene body were unaltered, suggesting ACTL6A



**Figure 6. ACTL6A overexpression leads to redistribution of H3K27me3 and activation of SCC genes**

(A) Heatmaps for H3K27me3 CUT&RUN differential 5-kb bins between primary human keratinocytes overexpressing ACTL6A and vector control. n = 2 experiments.

(B) Profiles over TSS with decreased (top) and increased (bottom) H3K27me3 levels upon ACTL6A overexpression versus vector control by CUT&RUN. Right: H3K4me3 chromatin immunoprecipitation sequencing (ChIP-seq) profiles of human keratinocytes (ENCODE).

(C) Scatterplot of H3K27me3 and RNA fold changes for genes with differential H3K27me3 levels upon ACTL6A overexpression. Color codes: H3K4me3 levels, high versus low or negative (neg).

(D) Heatmap showing ACTL6A-dependent PRC target genes with corresponding transcriptional changes in SCC tumors. H3K27me3: CUT&RUN as in (A). RNA: HNSC and LUSC tumor versus normal tissue from GEPIA 2.

(E) Genome browser tracks at the bivalent *WNT7B* gene upon ACTL6A overexpression (+) compared with vector control (-).

(F) *WNT7B* medium expression levels in tumors and paired normal tissues across various cancers. Data from GEPIA 2. BLCA, bladder urothelial carcinoma; LUAD, lung adenocarcinoma; CHOL, cholangiocarcinoma; LGG, brain lower-grade glioma; PRAD, prostate adenocarcinoma; PAAD, pancreatic adenocarcinoma; BRCA, breast invasive carcinoma; OV, ovarian serous cystadenocarcinoma; THYM, thymoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; GBM, glioblastoma multiforme; STAD, stomach adenocarcinoma; SKCM, skin cutaneous melanoma.

(G) Model for the ACTL6A-amplification-driven oncogenic mechanism in SCCs. Amplification or overexpression of ACTL6A leads to full occupancy of BAF complexes, giving rise to two mechanisms promoting SCC initiation and maintenance.

incorporation did not affect BAF chromatin binding but instead affected its activity in antagonizing PRCs (Figure 6E). Upregulation of *WNT7B* occurred in several types of SCCs, including HNSCs and LUSCs, as well as cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) and esophageal carcinoma (ESCA) (Figure 6F).

Besides *WNT7B*, other identified ACTL6A-dependent PRC targets known to play roles in SCC oncogenesis included *TWIST1*, which is associated with the epithelial-mesenchymal transition (EMT) in esophageal and head-and-neck SCCs (Jouppila-Mättö et al., 2011; Lee et al., 2012), and *SATB2*, which drives carcinogenesis of oral SCC, as well as other cancers, and

promotes the survival and chemoresistance of head-and-neck SCCs partly by interacting with  $\Delta Np63\alpha$  (Chung et al., 2010; Ge et al., 2020b; Seong et al., 2015; Yu et al., 2017) (Figure 6D). Several other ACTL6A-dependent PRC target genes belong to the FOX family, members of which are often repressed by polycomb and poised for activation (Golson and Kaestner, 2016). *FOXD1* upregulation induces EMT and chemoresistance of oral SCC cells (Chen et al., 2021), and *FOXL2* is upregulated in SCC tumors and a driver of granulosa-cell tumors (Ge et al., 2020a; Shah et al., 2009). Another ACTL6A-dependent PRC target, *CDKN2A*, is considered a tumor suppressor; however, overexpression of *CDKN2A* has been noted in several tumors, including SCC tumors (Romagosa et al., 2011). Altogether, our results suggest that before malignant transformation, early ACTL6A overexpression in epithelial cells is sufficient to reduce polycomb-mediated repression of genes necessary for SCC oncogenesis by perturbing chromatin architecture and BAF-PRC opposition.

## DISCUSSION

Our studies reveal that *ACTL6A* gene amplification and/or overexpression leads to its increased occupancy within BAF complexes that then facilitates the establishment of an altered chromatin state for SCC development (Figure 6G). BAF subunits are highly dosage sensitive (Kadoch and Crabtree, 2015). Mutations of BAF-subunit genes implicated in human cancers and neurological disorders such as autism and intellectual disability are commonly heterozygous, indicating that a half-normal level is biologically significant (Kadoch and Crabtree, 2015). Thus, the 2- to 4-fold increase of *ACTL6A* levels in SCCs and the consequent increase in ACTL6A occupancy within the complex are consistent with the dosage-sensitive role for BAF complexes in human diseases. Our studies show that reductions of *ACTL6A* levels result in alterations in chromatin accessibility of the SCC genome and that altering *ACTL6A* dosage has two consequences. First, complexes with stoichiometric occupancy of BAF are more effective at evicting polycomb from bivalent promoters; and second, ACTL6A-BAF's function prepares enhancers to receive signals mediated by TEAD-YAP (Figure 6G). These findings are consistent with previous studies showing that BAF complexes are required for the activation of both enhancers and polycomb-regulated bivalent promoters (Hodges et al., 2018; Nakayama et al., 2017). Our studies indicate that both mechanisms are critical and likely to function as an epigenetic AND gate for SCC initiation and maintenance. The requirement of both ACTL6A-dependent mechanisms likely explains the oncogenic specificity of *ACTL6A* amplification.

In the development of the mammalian nervous system, ACTL6A exchanges with ACTL6B to generate neuron-specific BAF complexes that coordinate gene expression underlying cell-cycle exit and the initiation of neural differentiation (Braun et al., 2021; Lessard et al., 2007). In epithelial cells, ACTL6A levels fall as the cells differentiate. This reduction triggers a programmatic switch from proliferation to keratinocyte differentiation, with the activation of keratinocyte differentiation genes including *KLF4* (Bao et al., 2013). ACTL6A is also essential for

proliferation and maintenance of stem cell potency (Krasteva et al., 2012; Lu et al., 2015). Thus, we propose that the degree of occupancy of ACTL6A in chromatin remodelers is regulatory and its dosage acts as a decisive signal underlying the transition between chromatin states during the initiation of SCCs.

Intriguingly, in contrast to SCCs with *ACTL6A* amplification, basal cell carcinoma (BCC), another cancer originating from basal epithelial cells, has a high frequency of heterozygous loss-of-function mutations in the BAF-subunit gene *ARID1A* (Bonnilla et al., 2016), whereas such mutations are rare in SCCs (Figure 1A). This indicates that different epidermal lineages (Sánchez-Danés and Blanpain, 2018) are specifically susceptible to distinct BAF complex alterations and illustrates the biologic specificity of their functions. Recent structural studies (He et al., 2020; Mashtalir et al., 2020) suggest that this specificity emerges from combinatorial assembly of the products of 29 genes encoding the 15 subunits, creating composite surfaces at their interfaces that are available to interact with proteins such as TEADs and YAP.

Considerable effort has been dedicated to developing TEAD/YAP/TAZ small-molecule inhibitors, with limited success (Calses et al., 2019). We found that ACTL6A incorporation promotes TEAD-YAP binding to BAF complexes, and the mutual dependency of BAF and TEAD-YAP creates a positive feedback mechanism to enhance their chromatin co-binding and promote transcriptional activity, suggesting a new therapeutic approach. The activating effects of ACTL6A as a BAF subunit on the TEAD-YAP pathway are consistent with genetic studies in flies, in which mutations in Brahma, the fly homolog of the SWI/SNF ATPase, hinder transcriptional activation by Yorkie (YAP homolog) (Jin et al., 2013; Oh et al., 2013). Our findings also support studies in breast epithelial lineage commitment, in which BAF complexes interact with the Hippo pathway component TAZ and positively regulate TAZ-induced transcription (Skibinski et al., 2014). Our CUT&RUN genome-wide mapping of the BAF complex and TEAD-YAP elucidate their co-occupancy across the genome and reveal the co-dependency of TEAD-YAP and ACTL6A-containing BAF complexes to bind to enhancers, which hence prepare the chromatin landscape to allow TEAD-YAP-mediated transcription at target loci. How P373S/P374G mutations facilitate the interaction between BAF complexes and TEAD-YAP is unclear, and we speculate that perhaps mutating the rigid proline-proline motif might make the loop structure more flexible and create more room for the interaction. Although ACTL6A reduction decreases the accessibility of TEAD enhancers, we found overexpression of *ACTL6A* alone in keratinocytes is not sufficient to significantly create new TEAD-accessible sites or further enhance the accessibility of TEAD elements (data not shown). We did observe genome-wide chromatin accessibility changes, particularly at FOX binding motifs, upon *ACTL6A* overexpression (data not shown), but further investigation will be needed to decipher the mechanisms underlying the specificity of effects induced by *ACTL6A* overexpression, as well as possible consequences of overexpression of other BAF-subunit genes. Our data suggest already-accessible TEAD elements in keratinocytes might not be further increased by *ACTL6A* overexpression and additional signals or co-alterations of BAF and TEAD-YAP might be required to make new TEAD sites accessible.

Others (Saladi et al., 2017) have reported that ACTL6A activates YAP by an indirect mechanism, wherein ACTL6A, in collaboration with TP63, controls YAP nuclear localization by repressing genes, including WWC1, that modulate YAP nuclear-cytoplasm shuttling. However, we did not detect changes in YAP subcellular localization upon ACTL6A loss; instead, we found that BAF complexes directly interact with YAP and TEAD and the interaction depends on ACTL6A.

Besides TEAD-YAP modulation, we found ACTL6A overexpression is sufficient to induce polycomb redistribution, resulting in the activation of genes known to have roles in SCCs. Although the exact mechanism of BAF-PRC antagonism remains unknown, the effects could be rooted in altered SMARCA4/SMARCA2 ATPase activity, which is required for BAF complexes to evict PRC1 (Kadoch et al., 2017; Stanton et al., 2017) and in yeast is promoted by the ACTL6A homologs Arp7/9 (Szerlong et al., 2008). The outcomes of ACTL6A-induced polycomb redistribution are rather selective for bivalent genes such as *WNT7B*, whose role in tumor initiation merits further investigation given the early occurrence of ACTL6A amplification during SCC development (Jamal-Hanjani et al., 2017), as does the role of ACTL6A in the interplay between BAF and PRC complexes. Despite its high mutation rate, *CDKN2A* is overexpressed in some SCC tumors (Romagosa et al., 2011) and the reduction of polycomb repression at *CDKN2A* upon ACTL6A overexpression might contribute to SCC oncogenesis. In line with this, polycomb removal and *CDKN2A* activation have also been found upon *SMARCB1* reexpression in *SMARCB1*-deficient tumor cells (Kia et al., 2008).

In summary, our studies demonstrate that altering subunit stoichiometry within a chromatin regulatory complex can be oncogenic and that the dynamics of ACTL6A occupancy in BAF complexes may play roles in normal development by enabling protein-protein interactions with key regulators engaged in proliferation and stem cell function. Our studies indicate that both polycomb redistribution and TEAD-YAP facilitation are essential downstream mechanisms for the initiation and maintenance of SCCs. Therefore, therapeutic efforts might be directed toward reducing ACTL6A function or stoichiometry. The discovery that mutations of two adjacent residues in ACTL6A enhance TEAD-YAP binding to BAF complexes and SCC proliferation suggests a precise therapeutic target.

### LIMITATIONS OF THE STUDY

This study primarily employs an *in vitro* cell culture system. Thus, further exploration of the link between ACTL6A dosage and TEAD-YAP/TAZ activation using *in vivo* models could better define the relevance of this mechanism in human cancers and how and when it contributes to SCC etiology. In addition, many hallmarks of cancer, such as metastasis, cellular signaling in the tumor microenvironment, immune cell infiltration, and angiogenesis, are absent from the cell culture systems, and the potential role or roles of ACTL6A in regulating the genes involved in these processes are outside the reach of this study. The depletion of ACTL6A and YAP/TAZ by siRNA- and CRISPR-based methods took 48 to 72 h, and it would be necessary to use auxin-inducible degron (AID) or other protein degrada-

tion technologies that allow rapid ACTL6A degradation to separate immediate from secondary effects. Direct recruitment of ACTL6A-containing versus ACTL6A-absent BAF complexes to polycomb-bound domains could also provide minute-by-minute kinetic analysis addressing the underlying mechanism of ACTL6A's role in BAF-polycomb antagonism that is absent from this study.

### STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Mammalian cell lines and culture conditions
- METHOD DETAILS
  - Estimate of protein molecules
  - ACTL6A and YAP/TAZ knockdown
  - ACTL6A overexpression
  - Immunoprecipitation and western blot
  - *In vitro* binding
  - Density gradient sedimentation analysis
  - Subcellular fractionation
  - Immunofluorescence
  - RNA extraction, qRT-PCR, and RNA-seq analysis
  - CUT&RUN and data analysis
  - Omni-ATAC-seq and data analysis
- QUANTIFICATION AND STATISTICAL ANALYSIS

### SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.molcel.2021.10.005>.

### ACKNOWLEDGMENTS

We thank all Crabtree laboratory members for intellectual input and suggestions, B. Keyes and W. Lu for critical reading of the manuscript, and S. Henikoff for providing protein A-MNase (pA-MN) for CUT&RUN. C.-Y.C. is supported by the GSK Sir James Black fellowship. Z.S. is supported by an EMBO Long-Term Fellowship (EMBO ALTF 1119-2016) and by a Human Frontier Science Program Long-Term Fellowship (HFSP LT 000835/2017-L). S.G.L. is supported by NIH grant CA243442. G.R.C. is an investigator of the Howard Hughes Medical Institute. This work was supported by the Howard Hughes Medical Institute, NIH grant CA163915, Department of Defense grant W81XWH-16-1-0083 (to G.R.C.), and the David Korn Professorship. K.M.L. is a Packard Foundation Fellow, Pew Scholar, Human Frontiers Science Program Young Investigator, and the Anthony DiGenova Endowed Faculty Scholar and is supported by the Stanford Ludwig Center for Cancer Stem Cell Research. W.J.G. is a Chan Zuckerberg Biohub investigator and acknowledges grants 2017-174468 and 2018-182817 from the Chan Zuckerberg Initiative.

### AUTHOR CONTRIBUTIONS

G.R.C. and C.-Y.C. conceived the project, designed the experiments, and wrote the manuscript. C.-Y.C. conducted all experiments. Z.S. performed

the bioinformatic analyses and assisted with experiments. S.G.L., A.K., and X.X. assisted with experiments. K.M.L. provided conceptual insights and assisted with experiments. W.J.G. advised on data analysis and provided conceptual insights. All authors read and approved the manuscript.

#### DECLARATION OF INTERESTS

G.R.C. is a founder and stockholder in Foghorn Therapeutics.

Received: March 3, 2021

Revised: August 25, 2021

Accepted: October 4, 2021

Published: October 22, 2021

#### REFERENCES

- Arensman, M.D., Kovochich, A.N., Kulikauskas, R.M., Lay, A.R., Yang, P.T., Li, X., Donahue, T., Major, M.B., Moon, R.T., Chien, A.J., and Dawson, D.W. (2014). WNT7B mediates autocrine Wnt/ $\beta$ -catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma. *Oncogene* 33, 899–908.
- Bao, X., Tang, J., Lopez-Pajares, V., Tao, S., Qu, K., Crabtree, G.R., and Khavari, P.A. (2013). ACTL6a enforces the epidermal progenitor state by suppressing SWI/SNF-dependent induction of KLF4. *Cell Stem Cell* 12, 193–203.
- Barisic, D., Stadler, M.B., Iurlaro, M., and Schübeler, D. (2019). Mammalian ISWI and SWI/SNF selectively mediate binding of distinct transcription factors. *Nature* 569, 136–140.
- Bass, A.J., Watanabe, H., Mermel, C.H., Yu, S., Perner, S., Verhaak, R.G., Kim, S.Y., Wardwell, L., Tamayo, P., Gat-Viks, I., et al. (2009). SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. *Nat. Genet.* 41, 1238–1242.
- Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih, IeM., Conejo-Garcia, J.R., et al. (2015). Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. *Nat. Med.* 21, 231–238.
- Bonilla, X., Parmentier, L., King, B., Bezrukov, F., Kaya, G., Zoete, V., Seplyarskiy, V.B., Sharpe, H.J., McKee, T., Letourneau, A., et al. (2016). Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. *Nat. Genet.* 48, 398–406.
- Braun, S.M.G., Petrova, R., Tang, J., Krokhotin, A., Miller, E.L., Tang, Y., Panagiotakos, G., and Crabtree, G.R. (2021). BAF subunit switching regulates chromatin accessibility to control cell cycle exit in the developing mammalian cortex. *Genes Dev.* 35, 335–353.
- Calses, P.C., Crawford, J.J., Lill, J.R., and Dey, A. (2019). Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities. *Trends Cancer* 5, 297–307.
- Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2, 401–404.
- Chandler, R.L., Damrauer, J.S., Raab, J.R., Schisler, J.C., Wilkerson, M.D., Didion, J.P., Starmer, J., Serber, D., Yee, D., Xiong, J., et al. (2015). Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. *Nat. Commun.* 6, 6118.
- Chen, H.I., and Sudol, M. (1995). The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. *Proc. Natl. Acad. Sci. USA* 92, 7819–7823.
- Chen, S., Yang, M., Wang, C., Ouyang, Y., Chen, X., Bai, J., Hu, Y., Song, M., Zhang, S., and Zhang, Q. (2021). Forkhead box D1 promotes EMT and chemoresistance by upregulating lncRNA CYTOR in oral squamous cell carcinoma. *Cancer Lett.* 503, 43–53.
- Chung, J., Lau, J., Cheng, L.S., Grant, R.I., Robinson, F., Ketela, T., Reis, P.P., Roche, O., Kamel-Reid, S., Moffat, J., et al. (2010). SATB2 augments  $\Delta$ Np63 $\alpha$  in head and neck squamous cell carcinoma. *EMBO Rep.* 11, 777–783.
- Ciriello, G., Miller, M.L., Aksoy, B.A., Senbabaoglu, Y., Schultz, N., and Sander, C. (2013). Emerging landscape of oncogenic signatures across human cancers. *Nat. Genet.* 45, 1127–1133.
- Clapier, C.R., Iwasa, J., Cairns, B.R., and Peterson, C.L. (2017). Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes. *Nat. Rev. Mol. Cell Biol.* 18, 407–422.
- Clark, J., Rocques, P.J., Crew, A.J., Gill, S., Shipley, J., Chan, A.M., Gusterson, B.A., and Cooper, C.S. (1994). Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. *Nat. Genet.* 7, 502–508.
- Corces, M.R., Trevino, A.E., Hamilton, E.G., Greenside, P.G., Sinnott-Armstrong, N.A., Vesuna, S., Satpathy, A.T., Rubin, A.J., Montine, K.S., Wu, B., et al. (2017). An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. *Nat. Methods* 14, 959–962.
- Corces, M.R., Granja, J.M., Shams, S., Louie, B.H., Seoane, J.A., Zhou, W., Silva, T.C., Groeneveld, C., Wong, C.K., Cho, S.W., et al.; Cancer Genome Atlas Analysis Network (2018). The chromatin accessibility landscape of primary human cancers. *Science* 362, eaav1898.
- Debaugnies, M., Sánchez-Danés, A., Rorive, S., Raphaël, M., Liagre, M., Parent, M.A., Brisebarre, A., Salmon, I., and Blanpain, C. (2018). YAP and TAZ are essential for basal and squamous cell carcinoma initiation. *EMBO Rep.* 19, e45809.
- Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15–21.
- Dodonova, S.O., Zhu, F., Dienemann, C., Taipale, J., and Cramer, P. (2020). Nucleosome-bound SOX2 and SOX11 structures elucidate pioneer factor function. *Nature* 580, 669–672.
- Dykhuizen, E.C., Hargreaves, D.C., Miller, E.L., Cui, K., Korshunov, A., Kool, M., Pfister, S., Cho, Y.J., Zhao, K., and Crabtree, G.R. (2013). BAF complexes facilitate decatenation of DNA by topoisomerase II $\alpha$ . *Nature* 497, 624–627.
- Ezhkova, E., Pasolli, H.A., Parker, J.S., Stokes, N., Su, I.H., Hannon, G., Tarakhovskiy, A., and Fuchs, E. (2009). Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. *Cell* 136, 1122–1135.
- Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* 6, p11.
- Ge, J., Jiang, L., Tian, Y., Zheng, M., Huang, M., and Li, J. (2020a). FOXL2 expression might be a novel prognostic biomarker in patients with laryngeal squamous cell carcinoma. *J. Int. Med. Res.* 48, 300060520919252.
- Ge, X., Gao, J., Sun, Q.W., Wang, C.X., Deng, W., Mao, G.Y., Li, H.Q., Guo, S.S., Cheng, J., Wu, Y.N., and Ye, J.H. (2020b). MiR-34a inhibits the proliferation, migration, and invasion of oral squamous cell carcinoma by directly targeting SATB2. *J. Cell. Physiol.* 235, 4856–4864.
- Golson, M.L., and Kaestner, K.H. (2016). Fox transcription factors: from development to disease. *Development* 143, 4558–4570.
- He, S., Wu, Z., Tian, Y., Yu, Z., Yu, J., Wang, X., Li, J., Liu, B., and Xu, Y. (2020). Structure of nucleosome-bound human BAF complex. *Science* 367, 875–881.
- Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., Singh, H., and Glass, C.K. (2010). Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* 38, 576–589.
- Heselmeyer, K., Schröck, E., du Manoir, S., Blegen, H., Shah, K., Steinbeck, R., Auer, G., and Ried, T. (1996). Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. *Proc. Natl. Acad. Sci. USA* 93, 479–484.
- Ho, L., Miller, E.L., Ronan, J.L., Ho, W.Q., Jothi, R., and Crabtree, G.R. (2011). esBAF facilitates pluripotency by conditioning the genome for LIF/STAT3 signalling and by regulating polycomb function. *Nat. Cell Biol.* 13, 903–913.
- Hodges, H.C., Stanton, B.Z., Cermakova, K., Chang, C.Y., Miller, E.L., Kirkland, J.G., Ku, W.L., Veverka, V., Zhao, K., and Crabtree, G.R. (2018).

- Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers. *Nat. Struct. Mol. Biol.* **25**, 61–72.
- Jamal-Hanjani, M., Wilson, G.A., McGranahan, N., Birkbak, N.J., Watkins, T.B.K., Veeriah, S., Shafi, S., Johnson, D.H., Mitter, R., Rosenthal, R., et al.; TRACERx Consortium (2017). Tracking the Evolution of Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* **376**, 2109–2121.
- Jin, Y., Xu, J., Yin, M.X., Lu, Y., Hu, L., Li, P., Zhang, P., Yuan, Z., Ho, M.S., Ji, H., et al. (2013). Brahma is essential for *Drosophila* intestinal stem cell proliferation and regulated by Hippo signaling. *eLife* **2**, e00999.
- Jouppila-Mättö, A., Närkiö-Mäkelä, M., Soini, Y., Pukkila, M., Sironen, R., Tuukkanen, H., Mannermaa, A., and Kosma, V.M. (2011). Twist and snai1 expression in pharyngeal squamous cell carcinoma stroma is related to cancer progression. *BMC Cancer* **11**, 350.
- Kadoch, C., and Crabtree, G.R. (2013). Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. *Cell* **153**, 71–85.
- Kadoch, C., and Crabtree, G.R. (2015). Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. *Sci. Adv.* **1**, e1500447.
- Kadoch, C., Hargreaves, D.C., Hodges, C., Elias, L., Ho, L., Ranish, J., and Crabtree, G.R. (2013). Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. *Nat. Genet.* **45**, 592–601.
- Kadoch, C., Williams, R.T., Calarco, J.P., Miller, E.L., Weber, C.M., Braun, S.M., Pulice, J.L., Chory, E.J., and Crabtree, G.R. (2017). Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states. *Nat. Genet.* **49**, 213–222.
- Keyes, W.M., Pecoraro, M., Aranda, V., Vernersson-Lindahl, E., Li, W., Vogel, H., Guo, X., Garcia, E.L., Michurina, T.V., Enikolopov, G., et al. (2011).  $\Delta$ Np63 $\alpha$  is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. *Cell Stem Cell* **8**, 164–176.
- Kia, S.K., Gorski, M.M., Giannakopoulos, S., and Verrizzer, C.P. (2008). SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. *Mol. Cell. Biol.* **28**, 3457–3464.
- Krasteva, V., Buscarlet, M., Diaz-Tellez, A., Bernard, M.A., Crabtree, G.R., and Lessard, J.A. (2012). The BAF53a subunit of SWI/SNF-like BAF complexes is essential for hemopoietic stem cell function. *Blood* **120**, 4720–4732.
- Krimpenfort, P., Snoek, M., Lambooi, J.P., Song, J.Y., van der Weide, R., Bhaskaran, R., Teunissen, H., Adams, D.J., de Wit, E., and Berns, A. (2019). A natural WNT signaling variant potentially synergizes with Cdkn2ab loss in skin carcinogenesis. *Nat. Commun.* **10**, 1425.
- Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**, 357–359.
- Lee, K.W., Kim, J.H., Han, S., Sung, C.O., Do, I.G., Ko, Y.H., Um, S.H., and Kim, S.H. (2012). Twist1 is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelial-mesenchymal transition. *Ann. Surg. Oncol.* **19**, 326–335.
- Lessard, J., Wu, J.I., Ranish, J.A., Wan, M., Winslow, M.M., Staahl, B.T., Wu, H., Aebersold, R., Graef, I.A., and Crabtree, G.R. (2007). An essential switch in subunit composition of a chromatin remodeling complex during neural development. *Neuron* **55**, 201–215.
- Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* **30**, 923–930.
- Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550.
- Lu, W., Fang, L., Ouyang, B., Zhang, X., Zhan, S., Feng, X., Bai, Y., Han, X., Kim, H., He, Q., et al. (2015). Act16a protects embryonic stem cells from differentiating into primitive endoderm. *Stem Cells* **33**, 1782–1793.
- Mashtalir, N., Suzuki, H., Farrell, D.P., Sankar, A., Luo, J., Filipovski, M., D'Avino, A.R., St Pierre, R., Valencia, A.M., Onikubo, T., et al. (2020). A Structural Model of the Endogenous Human BAF Complex Informs Disease Mechanisms. *Cell* **183**, 802–817.e24.
- McBride, M.J., Pulice, J.L., Beird, H.C., Ingram, D.R., D'Avino, A.R., Shern, J.F., Charville, G.W., Hornick, J.L., Nakayama, R.T., Garcia-Rivera, E.M., et al. (2018). The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma. *Cancer Cell* **33**, 1128–1141.e7.
- Nakayama, R.T., Pulice, J.L., Valencia, A.M., McBride, M.J., McKenzie, Z.M., Gillespie, M.A., Ku, W.L., Teng, M., Cui, K., Williams, R.T., et al. (2017). SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. *Nat. Genet.* **49**, 1613–1623.
- Nguyen, C.D.K., and Yi, C. (2019). YAP/TAZ Signaling and Resistance to Cancer Therapy. *Trends Cancer* **5**, 283–296.
- Oh, H., Slattery, M., Ma, L., Crofts, A., White, K.P., Mann, R.S., and Irvine, K.D. (2013). Genome-wide association of Yorkie with chromatin and chromatin remodeling complexes. *Cell Rep.* **3**, 309–318.
- Ramírez, F., Ryan, D.P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A.S., Heyne, S., Dündar, F., and Manke, T. (2016). deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res.* **44** (W1), W160–W165.
- Roberts, A., and Pachter, L. (2013). Streaming fragment assignment for real-time analysis of sequencing experiments. *Nat. Methods* **10**, 71–73.
- Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140.
- Romagosa, C., Simonetti, S., López-Vicente, L., Mazo, A., Lleonart, M.E., Castellvi, J., and Ramon y Cajal, S. (2011). p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. *Oncogene* **30**, 2087–2097.
- Ronan, J.L., Wu, W., and Crabtree, G.R. (2013). From neural development to cognition: unexpected roles for chromatin. *Nat. Rev. Genet.* **14**, 347–359.
- Ross-Innes, C.S., Stark, R., Teschendorff, A.E., Holmes, K.A., Ali, H.R., Dunning, M.J., Brown, G.D., Gojis, O., Ellis, I.O., Green, A.R., et al. (2012). Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. *Nature* **481**, 389–393.
- Saladi, S.V., Ross, K., Karaayvaz, M., Tata, P.R., Mou, H., Rajagopal, J., Ramaswamy, S., and Ellisen, L.W. (2017). ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis. *Cancer Cell* **31**, 35–49.
- Sánchez-Danés, A., and Blanpain, C. (2018). Deciphering the cells of origin of squamous cell carcinomas. *Nat. Rev. Cancer* **18**, 549–561.
- Schep, A.N., Wu, B., Buenrostro, J.D., and Greenleaf, W.J. (2017). chromVAR: inferring transcription-factor-associated accessibility from single-cell epigenomic data. *Nat. Methods* **14**, 975–978.
- Schlegelmilch, K., Mohseni, M., Kirak, O., Pruszk, J., Rodriguez, J.R., Zhou, D., Kreger, B.T., Vasioukhin, V., Avruch, J., Brummelkamp, T.R., and Camargo, F.D. (2011). Yap1 acts downstream of  $\alpha$ -catenin to control epidermal proliferation. *Cell* **144**, 782–795.
- Seong, B.K., Lau, J., Adderley, T., Kee, L., Chaukos, D., Pienkowska, M., Malkin, D., Thorner, P., and Irwin, M.S. (2015). SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization. *Oncogene* **34**, 3582–3592.
- Shah, S.P., Köbel, M., Senz, J., Morin, R.D., Clarke, B.A., Wiegand, K.C., Leung, G., Zayed, A., Mehl, E., Kalloger, S.E., et al. (2009). Mutation of FOXL2 in granulosa-cell tumors of the ovary. *N. Engl. J. Med.* **360**, 2719–2729.
- Shain, A.H., and Pollack, J.R. (2013). The spectrum of SWI/SNF mutations, ubiquitous in human cancers. *PLoS ONE* **8**, e55119.
- Shiah, S.G., Hsiao, J.R., Chang, W.M., Chen, Y.W., Jin, Y.T., Wong, T.Y., Huang, J.S., Tsai, S.T., Hsu, Y.M., Chou, S.T., et al. (2014). Downregulated miR329 and miR410 promote the proliferation and invasion of oral squamous cell carcinoma by targeting Wnt-7b. *Cancer Res.* **74**, 7560–7572.
- Simpson, D.R., Mell, L.K., and Cohen, E.E. (2015). Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. *Oral Oncol.* **51**, 291–298.

- Skene, P.J., Henikoff, J.G., and Henikoff, S. (2018). Targeted *in situ* genome-wide profiling with high efficiency for low cell numbers. *Nat. Protoc.* **13**, 1006–1019.
- Skibinski, A., Breindel, J.L., Prat, A., Galván, P., Smith, E., Rolfs, A., Gupta, P.B., LaBaer, J., and Kuperwasser, C. (2014). The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. *Cell Rep.* **6**, 1059–1072.
- Smeyne, R.J., Vendrell, M., Hayward, M., Baker, S.J., Miao, G.G., Schilling, K., Robertson, L.M., Curran, T., and Morgan, J.I. (1993). Continuous *c-fos* expression precedes programmed cell death *in vivo*. *Nature* **363**, 166–169.
- Speicher, M.R., Howe, C., Crotty, P., du Manoir, S., Costa, J., and Ward, D.C. (1995). Comparative genomic hybridization detects novel deletions and amplifications in head and neck squamous cell carcinomas. *Cancer Res.* **55**, 1010–1013.
- Stanton, B.Z., Hodges, C., Calarco, J.P., Braun, S.M., Ku, W.L., Kadoch, C., Zhao, K., and Crabtree, G.R. (2017). Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin. *Nat. Genet.* **49**, 282–288.
- Stein, C., Bardet, A.F., Roma, G., Bergling, S., Clay, I., Ruchti, A., Agarinis, C., Schmelzle, T., Bouwmeester, T., Schübeler, D., and Bauer, A. (2015). YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers. *PLoS Genet.* **11**, e1005465.
- Sturm, M., Schroeder, C., and Bauer, P. (2016). SeqPurge: highly-sensitive adapter trimming for paired-end NGS data. *BMC Bioinformatics* **17**, 208.
- Szerlong, H., Hinata, K., Viswanathan, R., Erdjument-Bromage, H., Tempst, P., and Cairns, B.R. (2008). The HSA domain binds nuclear actin-related proteins to regulate chromatin-remodeling ATPases. *Nat. Struct. Mol. Biol.* **15**, 469–476.
- Tamkun, J.W., Deuring, R., Scott, M.P., Kissinger, M., Pattatucci, A.M., Kaufman, T.C., and Kennison, J.A. (1992). *brahma*: a regulator of *Drosophila* homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. *Cell* **68**, 561–572.
- Tang, Z., Li, C., Kang, B., Gao, G., Li, C., and Zhang, Z. (2017). GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res.* **45** (W1), W98–W102.
- Tonon, G., Wong, K.K., Maulik, G., Brennan, C., Feng, B., Zhang, Y., Khatri, D.B., Protopopov, A., You, M.J., Aguirre, A.J., et al. (2005). High-resolution genomic profiles of human lung cancer. *Proc. Natl. Acad. Sci. USA* **102**, 9625–9630.
- Vincent-Mistiaen, Z., Elbediwy, A., Vanyai, H., Cotton, J., Stamp, G., Nye, E., Spencer-Dene, B., Thomas, G.J., Mao, J., and Thompson, B. (2018). YAP drives cutaneous squamous cell carcinoma formation and progression. *eLife* **7**, e33304.
- Wang, W., Xue, Y., Zhou, S., Kuo, A., Cairns, B.R., and Crabtree, G.R. (1996). Diversity and specialization of mammalian SWI/SNF complexes. *Genes Dev.* **10**, 2117–2130.
- Watanabe, H., Ma, Q., Peng, S., Adelmant, G., Swain, D., Song, W., Fox, C., Francis, J.M., Pedamallu, C.S., DeLuca, D.S., et al. (2014). SOX2 and p63 co-localize at genetic loci in squamous cell carcinomas. *J. Clin. Invest.* **124**, 1636–1645.
- Wenderski, W., Wang, L., Krokhotin, A., Walsh, J.J., Li, H., Shoji, H., Ghosh, S., George, R.D., Miller, E.L., Elias, L., et al. (2020). Loss of the neural-specific BAF subunit ACTL6B relieves repression of early response genes and causes recessive autism. *Proc. Natl. Acad. Sci. USA* **117**, 10055–10066.
- Wilson, B.G., and Roberts, C.W. (2011). SWI/SNF nucleosome remodelers and cancer. *Nat. Rev. Cancer* **11**, 481–492.
- Wilson, B.G., Wang, X., Shen, X., McKenna, E.S., Lemieux, M.E., Cho, Y.J., Koellhoffer, E.C., Pomeroy, S.L., Orkin, S.H., and Roberts, C.W. (2010). Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. *Cancer Cell* **18**, 316–328.
- Wu, J.I., Lessard, J., and Crabtree, G.R. (2009). Understanding the words of chromatin regulation. *Cell* **136**, 200–206.
- Yu, F.X., Zhao, B., and Guan, K.L. (2015a). Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. *Cell* **163**, 811–828.
- Yu, G., Wang, L.G., and He, Q.Y. (2015b). ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. *Bioinformatics* **31**, 2382–2383.
- Yu, W., Ma, Y., Shankar, S., and Srivastava, R.K. (2017). SATB2/ $\beta$ -catenin/TCF-LEF pathway induces cellular transformation by generating cancer stem cells in colorectal cancer. *Sci. Rep.* **7**, 10939.
- Zanconato, F., Forcato, M., Battilana, G., Azzolin, L., Quaranta, E., Bodega, B., Rosato, A., Bicciato, S., Cordenonsi, M., and Piccolo, S. (2015). Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. *Nat. Cell Biol.* **17**, 1218–1227.
- Zanconato, F., Cordenonsi, M., and Piccolo, S. (2016). YAP/TAZ at the Roots of Cancer. *Cancer Cell* **29**, 783–803.
- Zhang, Y., Liu, T., Meyer, C.A., Eeckhoutte, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., and Liu, X.S. (2008). Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* **9**, R137.
- Zhang, H., Liu, C.Y., Zha, Z.Y., Zhao, B., Yao, J., Zhao, S., Xiong, Y., Lei, Q.Y., and Guan, K.L. (2009). TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. *J. Biol. Chem.* **284**, 13355–13362.
- Zhang, J., Lee, D., Dhiman, V., Jiang, P., Xu, J., McGillivray, P., Yang, H., Liu, J., Meyerson, W., Clarke, D., et al. (2020). An integrative ENCODE resource for cancer genomics. *Nat. Commun.* **11**, 3696.
- Zhao, K., Wang, W., Rando, O.J., Xue, Y., Swiderek, K., Kuo, A., and Crabtree, G.R. (1998). Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling. *Cell* **95**, 625–636.

## STAR★METHODS

### KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Rabbit anti-Pan-TEAD (D3F7L)	Cell Signaling Technology	Cat# 13295S; RRID: AB_2687902
Mouse anti-TEAD4	Abcam	Cat# ab58310; RRID: AB_945789
Mouse anti-TEAD1	BD Biosciences	Cat# 610922; RRID: AB_398237
Mouse anti-BAF53A (ACTL6A)(5H3L6)	Invitrogen	Cat# 702414; RRID: AB_2665307
Mouse anti-ARID1A (PSG3)	Santa Cruz Biotechnology	Cat# sc-32761; RRID: AB_673396
Rabbit anti-BAF57 (SMARCE1)	Bethyl Laboratories	Cat# A300-810A; RRID: AB_577243
Rabbit anti-Phospho-YAP (Ser127) (D9W2I)	Cell Signaling Technology	Cat# 13008; RRID: AB_2650553
Mouse anti-Brg1 (SMARCA4) (H-10)	Santa Cruz Biotechnology	Cat# sc-374197 X; RRID: AB_10990135
Rabbit anti-INO80	Bethyl Laboratories	Cat# A303-371A; RRID: AB_10950580
Mouse anti-EZH2	BD Biosciences	Cat# 612666; RRID: AB_2102429
Rabbit anti-GAPDH (D16H11) XP	Cell Signaling Technology	Cat# 5174S; RRID: AB_10622025
Mouse anti-V5 tag	Invitrogen	Cat# R960-25; RRID: AB_2556564
Mouse IgG	Santa Cruz Biotechnology	Cat# sc-2025; RRID: AB_737182
Rabbit IgG	MilliporeSigma	Cat# 12-370; RRID: AB_145841
Mouse anti-YAP	Abnova	Cat# H00010413-M01; RRID: AB_535096
Rabbit anti-BAF53A (ACTL6A)	Novus Biologicals	Cat# NB100-61628; RRID: AB_958912
Mouse anti-FLAG (M2)	Sigma-Aldrich	Cat# F1804; RRID: AB_262044
Donkey anti-mouse IgG	Invitrogen	Cat# A-21202; RRID: AB_141607
Rabbit anti-TEAD1(D9X2L)	Cell Signaling Technology	Cat# 12292S; RRID: AB_2797873
Rabbit anti-histone H3K4me1	Abcam	Cat# ab8895; RRID: AB_306847
Rabbit anti-histone H3K4me3	Active motif	Cat# 39159; RRID: AB_2615077
Rabbit anti-histone H3K27me3	Cell Signaling Technology	Cat# 9733; RRID: AB_2616029
Rabbit anti-histone H3K27Ac	Abcam	Cat# ab4729; RRID: AB_2118291
Rabbit anti-BAF53A (ACTL6A)	The Crabtree laboratory	N/A
Rabbit anti-Brg1/BRM (SMARCA4/SMARCA2) (J1)	The Crabtree laboratory	N/A
Rabbit anti-BAF155 (SMARCC1)	The Crabtree laboratory	N/A
Rabbit anti-YAP (D8H1X) XP	Cell Signaling Technology	Cat# 14074S; RRID: AB_2650491
<b>Bacterial and virus strains</b>		
One-Shot Stbl3 chemically competent <i>E. coli</i>	Invitrogen	Cat# C7373-03
BL21(DE3) Competent <i>E. coli</i>	New England Biolabs	Cat# C25271
Rosetta 2(DE3) competent cells	EMD Millipore	Cat# 71397-3
<b>Chemicals, peptides, and recombinant proteins</b>		
Polybrene	Santa Cruz Biotechnology	Cat# sc-134220
Polyethylenimine Max (PEI MAX) (MW 40,000)	Polysciences	Cat# 24765
Digitonin	Millipore	Cat# 300410-250MG
Digitonin	Promega	Cat# G9441
Spermidine trihydrochloride	Sigma-Aldrich	Cat# S2501-1G
Benzonase Nuclease	Sigma-Aldrich	Cat# E1014-25KU
Amylose resin	New England Biolabs	Cat# E8021L
Glutathione-superflow resin	Clontech	Cat# 635608
Glutathione reduced	Sigma-Aldrich	Cat# G-4251
Dynabeads Protein A	Thermo Fisher Scientific	Cat# 10002D

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
3X FLAG Peptide	MilliporeSigma	Cat# F4799-4MG
Dynabeads Protein G	Thermo Fisher Scientific	Cat# 10009D
Geltrex	Thermo Fisher Scientific	Cat# A1413302
Transferrin	Roche	Cat# 10652202001
EGF	Thermo Fisher Scientific	Cat# PHG0311
Insulin	Sigma-Aldrich	Cat# I5500
Forskolin	Tocris Bioscience	Cat# 1099
VX-745	Tocris Bioscience	Cat# 3915
RO4929097	Cellagen Technology	Cat# C7649
Dexamethasone	Tocris Bioscience	Cat# 1126
Penicillin-Streptomycin	Thermo Fisher Scientific	Cat# 15140-163
Deoxyribonuclease I	Worthington Biochemical Corporation	Cat# LS002058
TRIsure	Bioline	Cat# BIO-38033
Plasmocin	InvivoGen	Cat# ant-mpp
Doxycycline	Sigma-Aldrich	Cat# D9891
Fibronectin	Sigma-Aldrich	Cat# F1141-1MG
DharmaFECT 1 transfection reagent	Horizon Discovery	Cat# T-2001-01
5X siRNA Buffer	Horizon Discovery	Cat# B-002000-UB-100
Puromycin dihydrochloride	Sigma-Aldrich	Cat# P8833-100mg
ON-TARGETplus Human ACTL6A siRNA	Horizon Discovery	Cat# L-008243-00
ON-TARGETplus Non-targeting Pool	Horizon Discovery	Cat# D-001810-10
Blasticidin S HCl	Thermo Fisher Scientific	Cat# R21001

**Critical commercial assays**

NEBNext Poly(A) mRNA Magnetic Isolation Module	New England Biolabs	Cat# E7490S
NEBNext MultiplexOligos for Illumina (Dual Index Primers Set 1)	New England Biolabs	Cat# E7600S
NEBNext High-Fidelity 2X PCR Master Mix	New England Biolabs	Cat# M0541S
Qubit dsDNA HS Assay Kit	Thermo Fisher Scientific	Cat# Q32854
ZymoPURE II Plasmid Midiprep Kit	Zymo Research	Cat# D4200
DNA Clean & Concentrator-5	Zymo Research	Cat# D4013
Direct-zol RNA Miniprep Kits	Zymo Research	Cat# R2050
High Sensitivity D1000 Reagents (Sample Buffer & Ladder)	Agilent Technologies	Cat# 5067-5585
High Sensitivity D1000 ScreenTapes	Agilent Technologies	Cat# 5067-5584
NextSeq 500/550 High Output Kit v2.5 (75 Cycles)	Illumina	Cat# 20024906
Bio-Rad Protein Assay Dye (Bradford)	Bio-Rad	Cat# 500-0006
Lenti-X GoStix	Clontech	Cat# 631281
PhiX Control v3	Illumina	Cat# FC-110-3001
SensiFAST SYBR Lo-ROX Kit	Bioline	Cat# BIO-94020
SensiFAST cDNA Synthesis Kit	Bioline	Cat# BIO-65054
KLD Enzyme Mix	New England Biolabs	Cat# M0554S
In-Fusion HD Cloning Kit	Clontech	Cat# 639650
NEBNext Ultra II DNA Library Prep with Sample Purification Beads	New England Biolabs	Cat# E7103S
NEBNext Ultra II Directional RNA Library Prep Kit	New England Biolabs	Cat# E7760S

**Deposited data**

Structure of nucleosome-bound human BAF complex	Protein Data Bank	PDB: 6LTJ
Deep sequencing datasets from this study	Gene Expression Omnibus	GEO: GSE156788

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
H3K4me3 ChIP-seq (keratinocytes)	ENCODE	Dataset: ENCSR075OQB
H3K27me3 ChIP-seq	ENCODE	Dataset: ENCSR377MRR
Original image data	Mendeley	Mendeley data: <a href="http://dx.doi.org/10.17632/gsd3wvy3nw.1">http://dx.doi.org/10.17632/gsd3wvy3nw.1</a>

Experimental models: Cell lines

Human Epidermal Keratinocytes, adult (HEKa)	Thermo Fisher Scientific	Cat# C0055C
HEK293T	Takara	Cat# 632180
FaDu	ATCC	Cat# HTB-43
NCI-H520	ATCC	Cat# HTB-182
T.T	JCRB Cell Bank	Cat# JCRB0262
KYSE70	Sigma	Cat# 94072012

Oligonucleotides

Primers	See <a href="#">Table S1</a>	N/A
---------	------------------------------	-----

Recombinant DNA

pQCXIH-Myc-YAP	Addgene	Cat# 33091
CYC244-Flag-NLS-hYAP	This study	N/A
N106-hACTL6A	This study	N/A
CYC103-hACTL6A	This study	N/A
pGSTag	Addgene	Cat# 21877
pMAL-c2X	Addgene	Cat# 75286
lentiCRISPR v2	Addgene	Cat# 52961
psPAX2	Addgene	Cat# 12260
pMD2.G	Addgene	Cat# 12259

Software and algorithms

Adobe Creative Cloud	Adobe	<a href="https://www.adobe.com/creativecloud.html">https://www.adobe.com/creativecloud.html</a>
Rstudio	RStudio	<a href="https://www.rstudio.com/">https://www.rstudio.com/</a>
Image Studio Lite	LI-COR	<a href="https://www.licor.com/bio/">https://www.licor.com/bio/</a>
SnapGene	Insightful Science	<a href="https://www.snapgene.com/">https://www.snapgene.com/</a>
Prism 8	GraphPad Software	<a href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</a>
SeqPurge	<a href="#">Sturm et al., 2016</a>	N/A
Bowtie2	<a href="#">Langmead and Salzberg, 2012</a>	N/A
deeptools	<a href="#">Ramírez et al., 2016</a>	N/A
macs2	<a href="#">Zhang et al., 2008</a>	N/A
Homer	<a href="#">Heinz et al., 2010</a>	N/A
DEseq2	<a href="#">Love et al., 2014</a>	N/A
edgeR	<a href="#">Robinson et al., 2010</a>	N/A
DiffBind	<a href="#">Ross-Innes et al., 2012</a>	N/A
chromVar	<a href="#">Schep et al., 2017</a>	N/A
ChIPseeker	<a href="#">Yu et al., 2015b</a>	N/A
ChrAccr	<a href="https://github.com/GreenleafLab/ChrAccr">https://github.com/GreenleafLab/ChrAccr</a>	N/A
PyMOL v2.4.2	Schrodinger	<a href="https://pymol.org/2/">https://pymol.org/2/</a>

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Gerald R. Crabtree ([crabtree@stanford.edu](mailto:crabtree@stanford.edu))

### Materials availability

Plasmids generated in this study will be available upon request.

### Data and code availability

- Next-generation sequencing data have been deposited at GEO and are publicly available as of the date of publication. Accession numbers are listed in the [key resources table](#). Original western blot images have been deposited at Mendeley and are publicly available as of the date of publication. Microscopy data reported in this paper will be shared by the lead contact upon request.
- This paper does not report any original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

### Mammalian cell lines and culture conditions

FaDu, a pharyngeal squamous cell carcinoma cell line, was purchased from ATCC (HTB-43) and cultured in ATCC-formulated Eagle's Minimum Essential Medium supplemented with 10% fetal bovine serum (FBS; Omega Scientific) and antibiotics (100 units/mL Penicillin and 100  $\mu$ g/mL Streptomycin; GIBCO). NCI-H520 lung squamous cell carcinoma cells were purchased from ATCC (HTB-182) and cultured in RPMI-1640 medium (ATCC modification, GIBCO) supplemented with 10% FBS and antibiotics. T.T esophageal squamous cell carcinoma cells were purchased from JCRB Cell Bank (JCRB0262) and cultured in medium Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12; GIBCO, catalog no. 10565) supplemented with 10% FBS, and antibiotics. KYSE70 esophageal squamous cell carcinoma cell line was purchased from Sigma (94072012) and cultured in medium RPMI-1640 (GIBCO, catalog no. 21870092) supplemented with 10% FBS, 10 mM HEPES (GIBCO), 1 mM sodium pyruvate (GIBCO), 2 mM GlutaMax (GIBCO) and antibiotics. Primary normal human epidermal keratinocytes (KC) were purchased from GIBCO (C0055C) and cultured on Geltrex (GIBCO) coated plates with EpiLife basal medium with 60  $\mu$ M calcium (GIBCO) plus 5  $\mu$ g/mL insulin, 15  $\mu$ g/mL transferrin, 10ng/mL epidermal growth factor, 10  $\mu$ M forskolin, 500nM VX-745, 250nM RO4929097, 100nM dexamethasone and antibiotics. HEK293T cells were purchased from Takara Bio USA (632180) and cultured in high glucose DMEM (GIBCO) medium supplemented with 10% FBS (GIBCO), 10 mM HEPES (GIBCO), 1 mM sodium pyruvate (GIBCO), 2 mM GlutaMax (GIBCO) and antibiotics. Cells were maintained in a humidified incubator at 37 °C in the presence of 5% CO<sub>2</sub> and passaged every 2–3 days. Cell lines were routinely tested for mycoplasma and immediately tested upon suspicion. None of the cell lines used in the reported experiments tested positive.

## METHOD DETAILS

### Estimate of protein molecules

For the preparation of whole-cell lysates, cells were lysed in RIPA buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 20 mM NaF, 1 mM DTT, 1 mM sodium orthovanadate, 0.25 mM PMSF and protease inhibitors) supplemented with 5 mM MgCl<sub>2</sub> and 0.5 U/ul of Benzonase (Sigma). After the samples were kept on ice for 30 minutes, LDS sample buffer with final 2.5%  $\beta$ -mercaptoethanol was added, followed by boiling for 5 minutes. The extracts from 300,000 cells were subjected to SDS-PAGE and western blot analysis together with 1.25 ng, 5 ng, 10 ng, and 20 ng of purified ACTL6A or SMARCA4 recombinant proteins. Odyssey CLx LI-COR was used to analyze and quantify the western blot signals. The standard curves of signal to mass from the recombinant proteins were applied for estimating the amount of ACTL6A or SMARCA4/SMARCA2 from the cell lysates, which was further divided by the cell number (300,000) to obtain the mass (g) per cell, and then the number of molecules (N) per cell was calculated using the following formula:  $N = \text{mass (g)} / (\text{molecular weight (kDa)} \times 10^3) \times \text{Avogadro constant } (6.022 \times 10^{23})$

For producing recombinant proteins, the DNA fragment encoding human ACTL6A amino acid 43-119, the region used to raise anti-ACTL6A antibodies (Crabtree laboratory), was inserted between the BamHI and HindIII sites of pGSTag (Addgene 21877); and the fragment expressing human SMARCA4 amino acid 1086-1307, used to raise the J1 antibodies (Crabtree laboratory) that recognize both SMARCA4 and SMARCA2, was inserted between the BamHI and HindIII sites of pMAL-c2X (Addgene 75286). After 0.4mM IPTG induction for 2 hours at 37°C, the bacteria were collected and resuspended in PBS with 1mM EDTA, 1mM PMSF, 0.02% (~3mM)  $\beta$ -mercaptoethanol, and protease inhibitors. The cells were lysed by Diagenode Bioruptor for 15 min, high output. After 3,500 rpm spin for 10 mins, the supernatants were rotated with amylose resin (New England Biolabs) for MBP tag, or glutathione-superflow resin (Clontech) for GST tag overnight at 4°C. The resins were washed four times by PBS supplemented with 350mM NaCl, 0.1% Triton X-100, 1mM EDTA, 1mM PMSF, 0.02% (~3mM)  $\beta$ -mercaptoethanol, and protease inhibitors. The GST-tagged proteins were eluted by 10mM reduced glutathione (Sigma, 100mM stock made in 50mM Tris, pH7.6) in PBS (containing 1mM PMSF and 0.02% (~3mM)  $\beta$ -mercaptoethanol), and MBP-tagged proteins were eluted by 10mM maltose.

### ACTL6A and YAP/TAZ knockdown

siRNA transfections were performed using DharmaFECT 1 transfection reagents (Horizon Discovery) in antibiotics-free medium according to the manufacturer's instructions. The siRNA reagents were purchased from Horizon Discovery (ON-TARGETplus Human

ACTL6A siRNA (Dharmacon L-008243-00); control ON-TARGETplus Non-targeting Pool (Dharmacon D-001810-10); custom YAP siRNA (GACATCTTCTGGTCAGAGA); custom TAZ siRNA (ACGTTGACTTAGGAACTTT). siRNAs were resuspended in siRNA buffer (Horizon Discovery). Cells were collected either 48 or 72 hours after transfection, as specified in the figure legends.

CRISPR gRNAs were cloned into vector lentiCRISPR v2 (Addgene 52961). The sequences of human *ACTL6A* targeting gRNAs are: TAATGCTCTGCGTGTCCGA, ATGAGCGGCGGCGGTACGG, GCGTGTCCGAGGGAGAATA, AGATGACGGAAGCACATTAA. For producing lentiviral particles, lentiviral vectors (18  $\mu\text{g}$  per 15  $\text{cm}^2$  dish) together with packaging vectors pMD2.G (4.5  $\mu\text{g}$ ) and psPAX2 (13.5  $\mu\text{g}$ ) were delivered into lenti-X 293T cells (Clontech) using 108–144  $\mu\text{g}$  PEI MAX 40K (Polysciences, cat. 24765; stock 1  $\mu\text{g}/\mu\text{l}$ ) mixed in 1.8 mL Opti-MEM (GIBCO) according to the manufacturer's instructions. 12–16 hours after transfection, the medium was replaced by viral production medium (UltraCULTURE™ serum-free cell culture medium (Lonza) supplemented with 10mM HEPES (GIBCO), 1 mM sodium pyruvate (GIBCO), 2mM GlutaMax (GIBCO) and antibiotics (GIBCO)). 72 hr post-transfection, lentiviral particles were collected by centrifugation of 0.45  $\mu\text{m}$  pore size-filtered cell culture supernatants at 20,000 rpm for 2 hours at 4°C, followed by PBS resuspension. Lentiviral transduction was conducted by spinfection methods in the presence of 10  $\mu\text{g}/\text{ml}$  polybrene at 1,100  $\times\text{g}$  for 30 min at 37°C. 48 hours post-infection, infected cells were selected by 2  $\mu\text{g}/\text{ml}$  puromycin (Sigma), followed by 10  $\mu\text{g}/\text{ml}$  Blastidicin (GIBCO) in *ACTL6A* reconstitution experiments.

### ACTL6A overexpression

Human *ACTL6A* cDNA were cloned between Not1 and Mlu1 restriction enzyme sites downstream of the EF1 $\alpha$  promoter in Crabtree lentiviral vector CYC103 (puromycin selection) and N106 (blasticidin selection), which harbor a second promoter PGK driving drug resistance gene for selection. See the “ACTL6A knockdown” section for lentiviral production and infection. For site-directed mutagenesis, *ACTL6A* cDNA were cloned into pUC-19 vector between HindIII and Kpn1, and the construct was used as template in PCR with primers- for P373S/P374G: TCAGAAACTTCTGGAAGTATGCGG, GACAGCTCTCTATTCAAC; for R377G: TCCAAGTATGGG CTTGAAATTGATTGC, GGAGTTTTCTGAGACAGC. The PCR products were treated by kinase, ligase and Dpn1 (KLD) enzyme mix (New England Biolabs), followed by bacterial transformation, clone selection by Sanger DNA sequencing, and subcloning back to lentiviral vector CYC103 (puromycin selection) and N106 (blasticidin selection) between Not1 and Mlu1 sites. For generating *ACTL6A* expressing constructs that are resistant to *ACTL6A*-CRISPR KO, the following silent mutations marked by underlines were introduced to block *ACTL6A* gRNA binding: atgTCTggAggAgtCtaTgg, GgaCgaTggCTCTacCttGa, CaaCgcCctCAGGgtCcc-TCgCaAaata.

### Immunoprecipitation and western blot

For protein-protein interaction studies, cells reaching 80%–90% confluence on the culture plates were washed once by cold PBS and lysed in cold hypotonic lysis buffer A,  $\sim 0.5\text{ml}/10\text{cm}^2$  growth area (Buffer A: 25 mM HEPES pH 7.5, 25 mM KCl, 0.05 mM EDTA, 5mM MgCl<sub>2</sub>, 10% glycerol, 0.1% NP-40, 1 mM DTT, 1 mM sodium orthovanadate, 0.25 mM PMSF and protease inhibitors). After incubation on ice for 5 minutes, cells were scraped from plates by cell lifter, harvested, and spun down at 1500 rpm for 5 mins at 4°C. Then, the nuclei were washed by buffer A twice. For each wash, cold 5ml buffer A per 20-million cells were added to the pellet, followed by 5-minute incubation on ice, centrifugation at 1,500 rpm for 5 mins, and discarding the supernatants. The nuclei were lysed in immunoprecipitation (IP) buffer,  $\sim 1$  mL per 20-million cells (IP buffer: 20 mM HEPES pH7.5, 100 mM KCl, 2.5 mM MgCl<sub>2</sub>, 5% glycerol, 1% Triton X-100, 0.5% NP-40, 1 mM dithiothreitol (DTT), 1mM sodium orthovanadate, 0.25 mM phenylmethylsulphonyl fluoride (PMSF) and protease inhibitors). The nuclei were further passed through a 1 mL 27G-needle syringe 5 times and sonicated for three cycles of 10 s-ON and 1 minute-OFF, high output (Diagenode Bioruptor). After centrifugation at 15,000 rpm for 10 min to collect the supernatants, the concentrations of the nuclear extracts were measure by Bradford assay (Bio-Rad) and adjusted to 1–1.5  $\mu\text{g}/\mu\text{l}$  by IP buffer. For each IP, 500–1000ug protein extracts were incubated under rotary agitation overnight at 4°C with antibodies against SMARCA4 (Santa Cruz Biotechnology, sc-374197 X; 4  $\mu\text{g}$ ), YAP (Cell Signaling Technology, 14074S; 5  $\mu\text{l}$ ), Pan-TEAD (Cell Signaling Technology, 13295S; 5  $\mu\text{l}$ ), TEAD4 (Abcam, ab58310; 3ug), ACTL6A (Invitrogen, 702414; 2.5  $\mu\text{g}$ ), or mouse/rabbit IgG control (Santa Cruz Biotechnology sc-2025; MilliporeSigma, 12-370). After additional one hour incubation with 40ul Protein A or G dynabeads (Invitrogen), the beads were washed four times by 1 mL IP buffer and resuspended in 20  $\mu\text{l}$  1x LDS sample buffer (Invitrogen) containing 2.5%  $\beta$ -mercaptoethanol and then boiled at 95°C for 5 min. The samples were subjected to SDS-PAGE and western blot analysis. For *ACTL6A* perturbations, cells were collected 72 hours after siRNA transfection or 5 days after infection by lentiCRISPR, or 1–2 weeks after infection by lentivirus carrying *ACTL6A*.

Antibodies used for western blotting included those against SMARCC1 (Crabtree laboratory), SMARCA4 (Santa Cruz Biotechnology, sc-374197 X), ACTL6A (Novus Biologicals, NB100-61628; or homemade in the Crabtree laboratory), J1 SMARCA4/SMARCA2 (Crabtree laboratory), ARID1A (Santa Cruz Biotechnology, sc-32761), BAF57 (Bethyl Laboratories, A300-810A), YAP (Abnova, H00010413-M01; Cell Signaling Technology, 14074S), Phospho-YAP Ser127 (Cell Signaling Technology, 13008), Pan-TEAD (Cell Signaling Technology, 13295S), TEAD1 (BD Biosciences, 610922), TEAD4 (Abcam, ab58310), INO80 (Bethyl Laboratories, A303-371A), EZH2 (BD Biosciences, 612666), GAPDH (Cell Signaling Technology, 5174S), V5 (Invitrogen, R960-25).

### In vitro binding

To produce FLAG-YAP proteins in mammalian cells, doxycycline-inducible lentiviral plasmid CYC244-FLAG-NLS-hYAP was generated by cloning FLAG-NLS-hYAP DNA into Not1 restriction enzyme site downstream of the tetracycline response element (TRE) in

Crabtree lentiviral vector CYC244, which harbors a second promoter PGK driving puromycin-resistance gene and transactivator rTA. FLAG-NLS-hYAP DNA were amplified from pQCXIH-Myc-YAP (Addgene# 33091). See the “ACTL6A knockdown” section for lentiviral production and infection. 24 hours after doxycycline (0.5  $\mu\text{g}/\text{ml}$ ) addition, nuclear extracts from HEK293T cells were prepared as described in the “Immunoprecipitation and Western blot” section with modification of using 500mM KCl in the IP buffer (high-salt IP buffer), followed by immunoprecipitation using anti-FLAG antibody (Sigma-Aldrich, F1804) or mouse/rabbit IgG as control. After high-salt IP buffer wash, FLAG-YAP proteins were eluted by 3xFlag peptide (Sigma-Aldrich, F4799) in the IP buffer on the Thermomixer at 400 rpm for 10min at RT and the dynabeads were discarded after magnetic separation. To purify BAF complexes, nuclear extracts from HEK293T cells were prepared as above and a SMARCC1 antibody (Crabtree laboratory) was used for immunoprecipitation using high-salt IP buffer. After 5 time washes by high-salt IP buffer, the dynabeads bound by BAF complexes were resuspended in the IP buffer, incubated with the purified FLAG-YAP overnight, followed by 5-time IP buffer washing step. The dynabeads were resuspended in 1x LDS sample buffer (Invitrogen) containing 2.5%  $\beta$ -mercaptoethanol and then boiled at 95°C for 5 min. The samples were subjected to SDS-PAGE and western blot analysis.

### Density gradient sedimentation analysis

A detailed description has been published elsewhere (Lessard et al., 2007). In brief, 30-40 million cells were washed by PBS once, lysed in 10 mL cold hypotonic lysis buffer A (see Immunoprecipitation), and then incubated on ice for 7 minutes. After centrifugation at 1500 rpm for 5 mins at 4 °C, nuclei were further washed by 10 mL buffer A twice and re-suspended in 700  $\mu\text{l}$  buffer C (10 mM HEPES, pH7.5, 100 mM KCl, 0.1 mM EDTA, 3mM  $\text{MgCl}_2$ , 10% glycerol, 1 mM DTT, 1mM sodium orthovanadate, 0.25 mM PMSF and protease inhibitors). Chromatin proteins were extracted with 0.3M ammonium sulfate (pH 7) by adding 1/9 volume of 3M ammonium sulfate stock and incubated under rotary agitation for 1-2 hours at 4 °C. Nuclear extracts were collected after ultracentrifugation at 100,000 rpm for 15 minutes at 4 °C (TLA 120.2 rotor), and proteins were precipitated with 0.33  $\text{mg}/\mu\text{l}$  ammonium sulfate on ice for 20 min. Precipitated proteins were pelleted by another ultracentrifugation at 100,000 rpm for 15 minutes at 4 °C and re-suspended in 200  $\mu\text{l}$  HEMG-0 buffer (25 mM HEPES, pH7.9, 100 mM KCl, 0.1 mM EDTA, 12.5mM  $\text{MgCl}_2$  supplemented with 1 mM DTT, 1mM sodium orthovanadate, 0.25 mM PMSF and protease inhibitors). Protein concentration was measured by Bradford assay (Bio-Rad) and adjusted accordingly for glycerol gradient analyses. 200  $\mu\text{l}$  of the solution with 500-1000  $\mu\text{g}$  total protein was overlaid on a 10 mL density-gradient liquid column with 10 to 30% glycerol (in HEMG buffer) and placed in a SW-40 swing bucket rotor for centrifugation at 40,000 rpm for 16 h at 4°C. A series of 0.5ml fractions were then recovered top-down and subsequently subjected to SDS-PAGE and western blot analysis.

### Subcellular fractionation

Cells were first lysed in cold hypotonic lysis buffer A (Buffer A: 25 mM HEPES pH 7.5, 25 mM KCl, 0.05 mM EDTA, 5mM  $\text{MgCl}_2$ , 10% glycerol, 0.1% NP-40, 1 mM DTT, 1 mM sodium orthovanadate, 0.25 mM PMSF and protease inhibitors). After incubation on ice for 5 minutes, cells were spun down at 1500 rpm for 5 mins at 4 °C. The supernatants were collected as cytoplasmic fraction. Nuclei were washed by buffer A twice, lysed (in equal volume to the cytoplasmic fractions) with RIPA buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 20 mM NaF, 1 mM DTT, 1 mM sodium orthovanadate, 0.25 mM PMSF and protease inhibitors) supplemented with 5 mM  $\text{MgCl}_2$  and 0.5 U/ $\mu\text{l}$  of Benzonase (Sigma), and then incubated on ice for 30 minutes. Both cytoplasmic fractions and nuclei solutions were subjected to centrifugation at 15,000 rpm for 10 min at 4°C to remove the cell debris. Samples were diluted with 4x LDS sample buffer (Invitrogen)/ $\beta$ -mercaptoethanol, boiled for 5 minutes, and analyzed by western blot.

### Immunofluorescence

24 hours after siRNA transfection, cells were re-seeded onto chamber slides coated with fibronectin (coating: 20  $\mu\text{g}/\text{ml}$  fibronectin (Sigma) at 37°C overnight). 72 hours post-transfection, cells were fixed in 4% paraformaldehyde (PFA) for 10 min at room temperature (RT). For immunostaining, cells were permeabilized in PBS with 0.3% Triton X-100 for 20 min and blocked for 1h at RT in blocking buffer (PBS containing 2.5% normal donkey serum, 2.5% normal goat serum, 1% BSA and 0.1% Triton X-100) supplemented with M.O.M. blocking reagent (Vector Laboratories). Primary YAP antibody (Abnova, H00010413-M01) was diluted in blocking buffer supplemented with M.O.M. Protein Concentrate (Vector Laboratories) and applied to cells, followed by overnight incubation at 4°C. After washing with PBS+ 0.1% Triton X-100 three times at RT, cells were incubated for 1 hour at RT with secondary antibodies conjugated to Alexa 488 (Invitrogen). The slides were mounted with ProLong Diamond Antifade Mountant with DAPI (Invitrogen). Images were captured on the Keyence BZ-X700 microscope, and formatted using ImageJ, Adobe Photoshop, and Illustrator CS6.

### RNA extraction, qRT-PCR, and RNA-seq analysis

48 or 72 hours after siRNA transfection or one week after lentiviral transduction and drug selection, cells were lysed directly in culture plates with TRIzol reagents (Bioline), and RNA was extracted using Direct-zol RNA MiniPrep kits (Zymo Research) with in-column DNase I digestion to remove residual genomic DNA. For qRT-PCR, complementary DNA was synthesized using the SensiFAST cDNA synthesis kit (Bioline). cDNAs were mixed with indicated primers and SensiFAST SYBR lo-ROX reagents (Bioline), and quantitative PCR (qPCR) was performed on a Applied Biosystems QuantStudio 6 Flex Real-Time PCR System. Primer specificity was confirmed by subsequent melting curve analysis or gel electrophoresis. Levels of PCR products were expressed as a function of peptidylprolyl

isomerase B (*PP1B*). Primers were designed through Primer 3 or from previous reports, and amplified products encompass exon/intron boundaries. The primer sequences of primers used in this study are listed in [Table S1](#).

RNA-seq libraries were generated using the NEBNext ultra II directional RNA library prep kit coupled with NEBNext multiplex oligos for Illumina (New England Biolabs) and following the manufacturer's directions. PE75 sequencing was performed on a NextSeq 550 sequencing system (Illumina). Alignment of RNA-sequencing reads was performed with STAR ([Dobin et al., 2013](#)) with ENCODE standard options to GENCODE v19, and read counts were generated using eXpress ([Roberts and Pachter, 2013](#)). Differential gene expression was determined using DESeq2 ([Love et al., 2014](#)).

### CUT&RUN and data analysis

CUT&RUN was performed as previously described ([Skene et al., 2018](#)). Cells were collected 48 or 72 hours after siRNA transfection or one week after lentiviral transduction and drug selection. 250,000 cells were bound to 10  $\mu$ l concanavalin-A beads and collected into a 0.2 mL PCR tube. Antibody binding was conducted in the volume of 50  $\mu$ l on thermomixer for 96-well PCR plates (Eppendorf) in 4°C cold room for 2 hours, and Protein A-MNase binding for 1 hour. Wash buffer volume was adjusted to 150  $\mu$ l. The digestion was performed under high  $Ca^{2+}$ /low salt condition on ice for 15 minutes, followed by incubation at 37°C for 30 min to release CUT&RUN fragments. Antibodies were diluted 1/100 and included: YAP (Cell signaling, 14074T), TEAD1 (Cell signaling, 12292S), SMARCC1 (Crabtree laboratory), H3K4me1 (Abcam, ab8895), H3K4me3 (Active motif, 39159), H3K27Ac (Abcam, ab4729), H3K27me3 (cell signaling, 9733). For histone marks profiling, CUT&RUN fragments were purified by spin column-based methods (Zymo DNA clean & concentrator-5 kit). For transcription factors and BAF complex profiling, CUT&RUN fragments were extracted by phenol-chloroform to recover small fragments.

The libraries were generated using the NEBNext ultraII DNA library prep kit for Illumina coupled with NEBNext multiplex oligos for Illumina (New England Biolabs) with modifications optimized for small fragments (detailed in <https://dx.doi.org/10.17504/protocols.io.wvgfe3w>) PE75 sequencing was performed on a NextSeq 550 sequencing system (Illumina). Adaptor trimming was performed with SeqPurge ([Sturm et al., 2016](#)). Demultiplexed fastq files were mapped to the hg19 genome as 2  $\times$  36 mers using Bowtie2 ([Langmead and Salzberg, 2012](#)), and generated BAM files were then filtered for low-quality reads and duplicated reads. TEAD1 and YAP mapped fragments < 120bp were used for downstream analysis. Coverage bigwigs were generated using deeptools bamCoverage ([Ramírez et al., 2016](#)) with CPM normalization. Peaks were called using macs2 ([Zhang et al., 2008](#)) with the nomodel option. Fixed-width peaks from replicates and treatments were combined using the called peaks summits files as described previously ([Corces et al., 2018](#)). *De novo* motif search on all CUT&RUN libraries was done using Homer (v4.11) ([Heinz et al., 2010](#)) with default parameters. Counts over peaks were generated using featureCounts ([Liao et al., 2014](#)). Differential peaks were determined using DESeq2 ([Love et al., 2014](#)) or edgeR ([Robinson et al., 2010](#)). To annotate joined YAP/TEAD1/SMARCC1 peaks, we defined the following states based on CUT&RUN datasets: active promoter (high H3K4me3 & low H3K27me3 & TSS distance < 1000), poised promoter (high H3K4me3 & high H3K27me3 & TSS distance < 1000), active enhancer (high H3K4me1 & high H3K27Ac & TSS distance > 1000), poised enhancer (high H3K4me1 & high H3K27me3 & TSS distance > 1000) and repressed sites (H3K27me3 high). High and low were defined by 0.99 percentile.

Differential analysis for H3K27me3 CUT&RUN between *ACTL6A*-overexpressing and vector-control keratinocytes was performed using DiffBind ([Ross-Innes et al., 2012](#)) by binning the genome into 5-kb bins and performing differential analysis (using DESeq2) between the two conditions. We identified 4,035 H3K27me3-differential bins (constituting 2389 broad peaks), of which 1,963 showed decreased H3K27me3 levels upon *ACTL6A* overexpression. Genes with H3K27me3 differentials in their promoters were defined as genes whose TSS is within the differential H3K27me3 5-kb bin. H3K27me3 CUT&RUN and H3K4me3 ChIP-seq (ENCSTR075OQB for keratinocytes from ENCODE ([Zhang et al., 2020](#))) signals around gene promoter with differential H3K27me3 levels was performed using computeMatrix and plotProfile from deeptools ([Ramírez et al., 2016](#)). H3K27me3 ChIP-seq for keratinocytes were from ENCODE ENCSTR377MRR ([Zhang et al., 2020](#)). Heatmaps for CUT&RUN and ATAC-seq data around different genomic features were done using deeptools computeMatrix (v2.5.6) ([Ramírez et al., 2016](#)). Plots were generated using deeptools plotHeatmap or plotProfile. Differential gene expression data of RNA-seq for lung squamous cell carcinoma (LUSC) and head-and-neck squamous cell carcinoma (HNSC) versus their normal tissues were from GEPIA2 ([Tang et al., 2017](#)) with cutoff *p-value* < 0.05. HNSC and LUSC datasets were merged by gene name and then merged with genes displaying differential H3K27me3 CUT&RUN signals to identify *ACTL6A*-dependent polycomb target genes that were preferentially altered in either HNSC or LUSC tumors.

### Omni-ATAC-seq and data analysis

We followed the Omni-ATAC method in [Corces et al. \(2017\)](#). 72 hours after siRNA transfection or one week after lentiviral transduction and drug selection, cells were pretreated with 200 U/ml DNase (Worthington) for 30 min at 37°C to remove free-floating DNA and DNA from dead cells. Nuclei from 75,000 cells were used in the transposition reactions (Illumina) at 37°C for 30 min, followed by DNA purification by Zymo DNA clean & concentrator-5 kits, and library preparation. PE75 sequencing was conducted on a NextSeq 550 sequencing system (Illumina). Demultiplexed and trimmed fastq files were mapped to the hg19 genome as 2  $\times$  36 mers using Bowtie2 ([Langmead and Salzberg, 2012](#)). Duplicate reads were removed using picard-tools (v.1.99). Low-quality reads and chrM reads were removed using samtools. Fixed width peaks were called using macs2 ([Zhang et al., 2008](#)) with the nomodel option, and summits were called. Peaks from replicates and treatments were combined using the called peaks summits files as described previously

(Corces et al., 2018). Read counts over the peaks were done using the ChrAccR package (<https://github.com/GreenleafLab/ChrAccR>). Differential peaks were determined using DEseq2 (Love et al., 2014) or edgeR (Robinson et al., 2010).

To find transcription factors that are enriched in differential peaks, we used the motifMatcher (part of chromVar (Schep et al., 2017) package to call TF binding sites within the differential peak sets. Using hypergeometric testing, we computed the enrichment of each TF within increasing/decreasing differential peaks with all peaks as background. Heatmaps for CUT&RUN and ATAC-seq data around different genomic features were generated using deeptools computeMatrix (Ramirez et al., 2016) (v2.5.6). Plots were generated using deeptools plotHeatmap or plotProfile. Genomic feature annotation for ATAC-seq peaks that gained or lost accessibility as a result of *ACTL6A* loss was performed using ChIPseeker (Yu et al., 2015b).

### QUANTIFICATION AND STATISTICAL ANALYSIS

Comparisons were performed in Prism 8 (GraphPad Software) with unpaired two-tailed Student's t test to determine significance between two groups indicated in figures. The cancer genomic data were pulled from cBioPortal TCGA PanCancer Atlas studies (Cerami et al., 2012; Gao et al., 2013), and the RNA analyses of tumors versus paired normal tissues were pulled from GEPIA 2 (Tang et al., 2017).